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Abstract
Non-alcoholic fatty liver disease (NAFLD) is now the most common liver disease worldwide with 
its incidence closely linked to the rise in obesity. An estimated 20-30% of the UK population have 
fat accumulation in the liver (steatosis), which can progress to the more severe forms of NAFLD 
including steatohepatitis, fibrosis, cirrhosis and ultimately hepatocellular carcinoma. Fligh dietary 
intakes of fructose have been associated with fibrosis severity in NAFLD, however the molecular 
mechanisms for this remain unknown. The objective of these experiments was to develop an in 
vitro model of fructose-induced steatosis, initially, human hepatocytes (HepG2 liver ceil line) were 
treated with fructose (0-60 m M), with and without glucose, and iipid accumulation was measured 
after 4 8 ,7 2  and 96h. There was no evidence of steatosis or altered cell viability in response to 
fructose or glucose treatm ent at any time point measured. Subsequently, primary mouse 
hepatocytes were isolated for culture with and without fructose. Flowever, we observed that, 
regardless of glucose concentration in the isolation media (0 versus 5 m M) or in the seeding 
media (5 versus 25 mM), the primary hepatocytes appeared steatotic at very early time points (4, 
8 and 24h) after isolation and prior to fructose treatm ent. This is in contradiction to haematoxyiin 
and eosin stained liver sections from matched iittermates that exhibited no steatosis. Subsequent 
experiments aimed at manipulating both the primary hepatocyte isolation/seeding procedures to 
establish the cause of the steatosis observed immediately after seeding did not alter the extent of 
primary hepatocyte iipid content. Fatty acid treatments of the human liver cells under different 
culture conditions resulted in modest increase in hepatocyte iipid content, it was concluded that 
although fatty acid treatments could affect the HepG2 iipid content, fructose treatm ents of 
HepG2 cells do not alter HepG2 cell iipid content. Future studies should determine the extent of 
fructose metabolism in HepG2 and the fate of secondary metabolites of fructose, and whether 
fructose alters expression of the enzymes of lipogenesis.
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1 INTRODUCTION
1.1 The Liver's Roles Within the Body: Specific Functions
The hepatocytes of the liver coordinate 500 different metabolic functions, often in concert
with other organ systems (Maton et al, 1993). The liver performs a multitude of 
biosynthetic reactions. The majority of amino acid synthesis occurs in the hepatocytes 
(Lehninger et al, 2008). The liver plays various roles in the global coordination of the 
carbohydrate and iipid metabolism (Lehninger et ai, 2008). This includes glycogen synthesis 
and storage, plus giycogenolysis to release stored glycogen and gluconeogenesis (Campbell 
et ai, 2006; Widmaier, 2006). The liver is a major site for the synthesis and degradation of 
proteins, and for the urea cycle that converts ammonia to urea (Lehninger et ai, 2008). in 
addition, the liver also carries out various aspects of iipid metabolism, such as cholesterol 
synthesis (van der Wuip et ai, 2013), lipogenesis (Uyeda & Repa, 2006), and the formation 
of lipoproteins for transport of triacylglycerol (TAG) and cholesterol in the bloodstream  
(Lehninger et ai, 2008). The liver further assists iipid metabolism through its production and 
secretion of bile, which emulsifies dietary fats in the intestine while also aiding the 
absorption of fat-solubie vitamins (Lehninger et ai, 2008).
Equally, the liver also plays a part in the regulation of blood clotting through production of 
coagulation factors (Mercer & Chambers, 2013). Liver tissue is also the main site for the 
production of thrombopoietin, which is the main regulatory glycoprotein for the formation 
of blood platelets by bone marrow (Kato et al, 1998). The liver also synthesises the 
hormone insuiin-iike growth factor-1 (IGF-1) (Wu & Zhu, 2011), as well as serving as the site 
of degradation for other hormones such as insulin. A very important function of the liver is 
xenobiotic metabolism, in which toxic substances that have been absorbed are altered or 
degraded by méthylation, conjugation and giucuronidation (Jakoby & Ziegler, 1990).
1.1.1 Non-Alcoholic Fatty Liver Disease: Background and Definition
Non-alcoholic fatty-liver disease (NAFLD) describes a range of liver disorders observed in
individuals that do not consume a significant amount of alcohol (<10g/d for women, <20g/d  
for men) (Browning et ai. 2004). This spectrum ranges from "hepatic steatosis" to much 
more serious developments. Hepatic steatosis is the accumulation of triglyceride within 
iipid droplets (macrovesicies) in more than 5% of hepatocytes/5% of liver weight (Yeh & 
Brunt 2007). Hepatic steatosis is thought to be harmless, but can progress to more serious 
liver conditions, such as non-aicohoiic steatotic hepatitis (NASH), in which there is 
significant inflammation stemming from the reactive oxygen species (ROS) products of
mitochondrial dysfunction (Marrero et al. 2002). Further progression of NAFLD can lead to 
the development of fibrosis, cirrhosis, hepatocarcinoma and end-stage liver disease 
requiring liver transplant (Figure 1.1) (Bullock et al. 2004).
NAFLD is a prevalent feature observed in people that also have obesity, the metabolic 
syndrome, and type 2 diabetes (T2D), although this does not mean that those with obesity, 
the metabolic syndrome or T2D will always have NAFLD (Angelico et al. 2003). The 
association of NAFLD with insulin resistance (IR) has been suggested to be complicated by 
the question of how interrelated NAFLD and IR may be, and to what extent the conditions 
elicit or enhance each other (Utzschneider & Kahn 2006).
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Figure 1-1- The Natural History of Non-Alcoholic Fatty Liver Disease
(Torres et al. 2012). Natural history of both phenotypes of NAFLD including hepatic 
steatosis (also known as: Isolated Fatty Liver), which shows little risk for progression to 
cirrhosis or increased mortality, and NASH, which shows increased overall mortality as well 
as increased risk for cirrhosis and hepatocellular carcinoma. DM, Type II diabetes; ALT, 
alanine aminotransferase; AST aspartate aminotransferase.
1.1.2 The Epidemiology of Non-Alcoholic Fatty Liver Disease
NAFLD has become the most commonly encountered liver disease in the developed world,
with estimates ranging from 20-30% of the population having some stage of NAFLD 
(Matteoni et al. 1999). NAFLD can affect all age-ranges and ethnic groups, although the
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true scale of the prevalence of NAFLD is difficult to estimate for a variety of confounding 
reasons. The recorded incidence of confirmed diagnoses of NAFLD has increased 
dramatically in recent years, in parallel with the rise in incidence of obesity, provoking 
tremendous concern for various healthcare stakeholders (Charlton 2004).
Many risk factors, personal variables or medical conditions are associated with the 
incidence of NAFLD. Miscellaneous incidental factors can contribute to the development of 
NAFLD. These include surgery, treatm ent with certain drugs, rapid weight loss, and 
exposure to various environmental toxins (Adams & Angulo, 2006).
NAFLD can develop in persons from all age groups, although the prevalence of NAFLD has 
been documented to rise with increasing patient age (Fan et al. 2005, Frith et al. 2009, 
Chen et al. 2007). This association between age and NAFLD holds true across different 
cultures (Flamaguchi et al. 2005), and with increasing age, the NAFLD patient is subject to 
the more advanced features of the disease, such as fibrosis, resulting in a greater risk of 
mortality (Frith et al. 2009, Hossain et al. 2009, Kagansky et al. 2004). Male gender has 
been shown to be risk factor for NAFLD (Vernon et al. 2011); however, progression to NASH 
may predominate among women (Reid 2001).
It is not known exactly how the factors of ethnicity and race modify NAFLD. It may be that 
the association of other diseases such as obesity, metabolic syndrome and T2DM among 
people of Hispanic, Caucasian or African descent influence the corresponding association of 
NAFLD variables among each ethnic group. For instance, Hispanics display greater levels of 
hepatic steatosis, alanine aminotransferase (ALT) and the highest overall rate of NAFLD 
prevalence when compared to Caucasians and Blacks (Browning et al. 2004). These 
differences are suggestive of an inherited genetic susceptibility, and indeed the I148M  
polymorphism (rs738409) of the patatin-like phosphoiipase domain-containing protein 3 
(PNPLA3) gene has been identified as the causative factor in the heightened prevalence of 
steatosis and ALT-elevation among Hispanic people (Romeo et al. 2008).
T2D is an integral component of the metabolic syndrome. There is an association between 
NAFLD and T2D (Leite et al. 2009, Prashanth et al. 2009). The combination of T2D with 
NAFLD has been shown to enhance the associated risk of the progression of NAFLD towards 
the development of cirrhosis and increased patient mortality, in comparison with NAFLD 
patients without coincidental T2D (Younossi et al. 2004). The propensity for obesity and 
hypertriglyceridaemia among diabetics increases their risk of also developing fatty liver.
due to the increased rate of efflux of free fatty acids from adipocytes. The proposed cause 
of the failure to regulate lipolysis is IR (Adams et al. 2005).
The association of hypertriglyceridaemia with obesity and T2D means that it is also 
associated with NAFLD, although hypertriglyceridaemia may not necessarily be extricable 
from the other component features of the metabolic syndrome (Matteoni et al. 1999). The 
coincidence of hypertriglyceridaemia is correlated with the extent of hepatic steatosis 
when measured by ultrasound (Angelico et al. 2003). Obesity is an established risk factor 
for fatty liver. The performance of intraoperative liver biopsies prior to the treatm ent of 
obesity with bariatric surgery has provided robust information on the association of NAFLD 
and obesity (Ong et al. 2005). There is a particularly strong correlation between central 
(abdominal) obesity, as indicated by waist-to-hip ratio rather than mere body-mass index 
(BMI) score, and NAFLD and insulin resistance (Farrell & Larter 2006).
1.1.3 Clinical Features of Non-Alcoholic Fatty Liver Disease
The majority of patients with NAFLD or NAS FI are asymptomatic, although some may report
symptoms including fatigue and malaise, and a vague pain located in the upper-right 
quadrant of a patient's torso (Torres et al. 2012). Clinical investigation usually commences 
upon the discovery of abnormalities during routine investigation for reasons other than 
suspicion of NAFLD (Torres et al. 2012).
Significant alcohol usage must be excluded as a causative factor in order for a diagnosis of 
NAFLD. Abnormal liver functions test results constitute the most frequent feature when a 
patient presents with NAFLD. A modest elevation of the serum concentrations of ALT or 
aspartate aminotransferase enzyme (AST) is associated with NAFLD, while a patient who 
has developed NASH that is not evident from histological screening may present with 
higher levels of ALT and AST (Williams et al. 2011). The problem with relying on just serum 
aminotransferase enzyme levels is that as many as half of NASH patients may have 
histological signs of NASH, and yet have ALT/AST levels that occur within the normal range 
(Fracanzani et al. 2008). The elevation of gamma-glutamyltranspeptidase (GGT) in NAFLD 
patients is associated with a greater extent of liver fibrosis (Tahan et al. 2008), and an 
increased risk of death (Ruhl & Everhart 2009), with a greater correlation among male 
patients (Haring et al. 2009).
NAFLD could be thought of as the liver's version of the metabolic syndrome. An overweight 
or obese patient with the metabolic syndrome would present with abdominal obesity, 
fasting hyperglycaemia and hypertriglyceridaemia, lowered HDL cholesterol, and
hypertension. However, even if these features were present liver function test results may 
not necessarily reflect liver abnormality. Of confirmed NAFLD patients, 79% were found to 
have normal results for liver function (Browning et al. 2004).
1.1.4 Diagnosis of Non-Alcoholic Fatty Liver Disease
Assessment of steatosis can be performed via computed tomography, ultrasound 
sonography, and magnetic resonance imaging (MRI) (Dowman et al. 2011). The "gold- 
standard" method of diagnosing NAFLD is by a trained clinician performing a liver biopsy, 
and with reference made to the medical history of the patient. The liver biopsy is at present 
the only unequivocal means for determining a diagnosis for NAFLD, and even so, there are 
limits to the degree to which a biopsy can accurately predict the progression of the disease 
(Merriman et al. 2006, Ratziu et al. 2005, Yeh & Brunt 2007). Another considerable issue 
with biopsy is its invasive nature, though at present non-invasive methods have yet to be 
developed effectively enough for regular use in clinical practice (Wieckowska & Feldstein 
2008). Biopsy can confirm steatosis and allow histological assessment of the extent of 
disease progression. There may merely be simple steatosis, or there could be hepatocyte 
ballooning, necrosis and the infiltration of inflammatory cells such as eosinophils and 
lymphocytes. The amount and types of steatosis (whether macrovesicular or 
microvesicular, or mixed), as well as lobular formation and the development of any fibrosis 
is assessed according to scoring systems (Brunt et al. 1999, Kleiner et al. 2005).
1.2 The Pathogenic Mechanisms of Non-Alcoholic Fatty Liver 
Disease
Initially, the proposed pathogenic mechanism of NAFLD was thought to be comprised of 
two distinct insults, hence it being termed the "two-hit" hypothesis (Day & James 1998). As 
researchers have gathered more data, this two-hit model has been amended to reflect the 
multiple varying insults that convene upon the liver resulting in NAFLD development and 
progression (Charlton 2007). The component detrimental processes leading to 
hepatocellular injury may occur in concert with each other, without a distinct order of 
occurrence.
1.2.1 Hepatic Steatosis and Insulin Resistance
In the original model, the first suspected "hit" was the development of hepatic steatosis 
and the correlation of IR with hepatic steatosis (Figure 1.2). IR is a condition in which 
normal insulin secretion is no longer sufficient to produce adequate regulation of adipose, 
muscle and liver carbohydrate and lipid metabolism (Benhamed et al. 2012). IR in 
adipocytes of the visceral adipose tissue (VAT) results in a failure to regulate the activity of
hormone sensitive lipase (HSL) (Donnelly et al. 2005). The consequent rise in blood/serum  
concentrations of non-esterified fatty acids (NEFA), lead to an increase in the transport of 
NEFA into hepatocytes. The excess NEFA exceed the hepatocyte's ability to dispose of NEFA 
through (3-oxidation or by export from the cell as very low-density lipoprotein 
triacylglycerol (VLDL-TAG).
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Figure 1-2 - Mechanisms of Hepatic Lipid Accumulation.
(Dowman et al. 2009).
Lipid accumulation can arise in hepatocytes for a variety of reasons. This may be by 
increased delivery of NEFA delivered to the hepatocyte from VAT or from diet (Niklas et al. 
2012), or an increased conversion of carbohydrate to fatty acids in the liver (Benhamed et 
al. 2012). Decreased removal of fatty acids can contribute towards hepatic lipid 
accumulation, such as an impaired or insufficient rate of (3-oxidation of fatty acids within 
the hepatocyte or an impaired or insufficient export of fatty acid as VLDL-TAG out of the 
hepatocyte (Henkel et al. 2012).
1.2.2 Increased Inflammation
As peripheral IR contributes to hepatic steatosis due to a loss of control over lipolysis in 
visceral adipocytes, there is increased release of NEFA to the circulation that will be taken- 
up by the hepatocytes. Hepatic insulin resistance leads to failure to control hepatic glucose 
and lipid metabolism, with enhanced gluconeogenesis and increased de novo lipogenesis. 
As a key "second hit" of NAFLD, the activation of c-Jun N-terminal Kinase (JNK) proteins has 
a pronounced mechanistic role in the development of IR and in the promotion of apoptosis 
(Nguyen et al. 2005, Malhi et al. 2006). JNK-1 and JNK-2 are mitogen-activated protein
kinases (MAPKs), expressed in the liver. When activated, JNK-1 serine-phosphorylates c- 
Jun, leading to phosphorylation of insulin receptor substrate 1 (IRS-1) in steatohepatitis 
models, resulting in diminished insulin signalling and the development of IR (Tarantino & 
Caputi 2011, Weickert & Pfeiffer 2006). Some targets of JNK-activation include 
proapoptotic proteins such as Bim, BAD and BCI-2, triggering the process of mitochondrial 
apoptosis, particularly through the stimulation of JNK-activation by SFA (Malhi & Gores 
2008).
Another target of JNK is the inflammatory cytokine tumour necrosis factor alpha (TNFa) 
(Nguyen et al. 2005). Thus, JNK-activation promotes inflammation, mitochondrial damage 
and hepatocellular apoptosis, and JNK-1 expression has been positively correlated to the  
severity of IR (Tanti & Jager 2009). The increased de novo production of diacylgiyceroi 
(DAG) also compounds the problem of hepatic IR through the effects of DAG on the 
phosphorylation of IRS-1/2 (Jornayvaz & Shulman 2012), further diminishing the down­
stream signalling of insulin. Once activated, JNKs become involved in the development of 
IR, probably by through the covalent modification of downstream signalling molecules of 
the insulin-signalling pathway. Protein kinases such as JNK-1, and variants of Protein Kinase 
C (PKC), are known to serine and threonine-phosphorylate the IRS-1/2 molecules, leading 
to diminished insulin signal-transduction (Tarantino & Caputi 2011).
1.2.3 Mitochondrial Dysfunction and Oxidative Stress
Mitochondrial and peroxisomal fatty acid oxidation increases to try to compensate for the 
excessive NEFA supply. This may be partly due to stimulation of peroxisome proliferator 
activated receptor a  (PPARa) by some types of NEFA (Fluang & Jia et al. 2012), or by 
cytokines such as inteleukin-6 (IL-6) (Hong et al. 2004). The increased rate of |3-oxidation 
leads to enhanced flux of electrons through the mitochondrial respiratory chain (MRC). This 
likely leads to an increased production of ROS and to an increased level of oxidative stress 
upon the hepatocyte (Oliveira et al. 2006).
Alteration or distinct impairment of mitochondrial respiration due to excessive ROS 
production is common in NASH (Begriche et al. 2013). An effect of increased ROS from  
mitochondrial activity, or from the induction of cytochrome P450 2E1 (CYP2E1) in the ER 
and mitochondria, is damage to the enzymes of the MRC (Perez-Carreras et al. 2003). There 
may also be damage to mitochondrial DNA (Kawahara et al. 2007), which diminishes 
mitochondrial biogenesis (Aharoni-Simon et al. 2011, Valdecantos et al. 2012). Another 
source of ROS in NAFLD is the peroxisomal (3-oxidation of fatty acids (Schonfeld et al. 2009),
which creates H2 O2 as a by-product. The increased production of ROS then leads to the 
increased expression of TNFa, which can induce the hypoxia inducible fac to r-la  (H IF-la) 
transcription factor that plays an essential role in coordinating cellular response to hypoxia 
(Domenis et al. 2012). H IF -la  can perturb the expression of glycolytic and mitochondrial 
respiratory enzymes towards an "aerobic glycolytic" scheme via the mitochondrial ATPase 
inhibitory factor 1 (IF l), which regulates the activity of mitochondrial ATP synthase. This 
diminishes mitochondrial respiration, as well as causing damage to the mitochondrial 
genome.
Activation of JNK by excessive SFA also damages hepatocyte mitochondrial capability, 
through triggering apoptosis and the release of cytochrome c oxidase (Perez-Carreras et al.
2003) from the MRC, and increasing the permeability of the mitochondrial membrane, 
decreasing the membrane potential.
1.2.4 Lipotoxicity
Saturated fatty acids (SFA) are implicated in the "second hits" that influence the 
progression of NAFLD from benign hepatic steatosis. Hepatocyte cell death in NAFLD that is 
due to lipotoxicity is called lipoapoptosis (Kusminski et al. 2009). NAFLD and NASH severity 
correlates with the extent of lipoapoptosis (Feldstein et al. 2003, Ribeiro et al. 2004). The 
state of saturation of the NEFA that a hepatocyte is exposed to has influence over the 
degree of lipotoxicity that results, with SFA exerting greater lipotoxic effect than 
monounsaturated fatty acids (MUFA) (Malhi et al. 2006, Wei et al. 2006). Hepatocyte 
apoptotic paths converge on the mitochondria. The Bcl-2 group of proteins of the 
mitochondria regulate the apoptotic process. The Bcl-2 proteins are sub-divided into three 
groups: the anti-apoptotic proteins M c l-l and Bcl-1; the pro-apoptotic proteins like Bax; 
and the sensory BH3 proteins such as Bim and PUMA, which are attuned to intracellular 
messages to initiate cell-death (Malhi & Gores 2008). These factors are phosphorylated by 
JNK-activated protein kinases, initiating inflammation and apoptosis (Malhi & Gores 2008). 
SFA induce the activity of the pro-apoptotic BH3 proteins (Bim and PUMA), while 
attenuating the activities of the anti-apoptotic Bcl-2 proteins, such a M c l-l via protein 
kinase C (Cazanave et al. 2009, Barreyro et al. 2007). Another lipotoxic molecule is 
ceramide, the central lipid involved in sphingolipid metabolism. Increased availability of 
long-chain SFA enhances the production rate of ceramide within the endoplasmic reticulum  
(ER), to the point of excess (Morales et al. 2007). Excessive ceramide increases the  
activation of inflammatory cytokines such as TNFa, resulting in further IR (Morales et al. 
2007).
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1.2.5 Endoplasmic Reticulum Stress
Ordinarily, the ER provides an environment in which correct protein folding, through the 
actions of molecular chaperones, is assisted by degradation machinery that recognises, and 
earmarks improperly formed proteins for degradation by the proteasomes of the cytosol. 
The unfolded protein response (UPR) serves to regulate this function (Figure 1.3) 
(Pagliassotti 2012). ER stress is the disruption of ER homeostasis, typically resulting from an 
accumulation of misfolded proteins within the ER-lumen (Kaufman 1999). This disruption 
activates the UPR (Rutkowski & Hegde 2010), with consequences for the synthesis of cell 
membranes, insulin signalling, and inflammatory and apoptotic signalling pathways. ER 
stress and the UPR are implicated in both the development of hepatic steatosis and in the 
progression of NAFLD to NASH (Puri et al. 2008). Specific nutrients have been found to 
activate the UPR in the context of NAFLD. SFA induce ER-stress (Boden et al. 2011, W ei et 
al. 2006), and excessive glucose stimulates the hexosamine biosynthetic pathway, 
increasing the extent of protein glycosylation beyond that which normally occurs within the 
ER (Sage et al. 2010). This activates double-stranded RNA-dependent protein kinase (PKR)- 
like ER kinase (PERK) and limits apolipoprotein BlOO (apoB) VLDL export form the ER (Qiu et 
al. 2009). In in vitro models, fructose treatm ent has not yet been investigated as an inducer 
of ER-stress, although ER-stress was shown to mediate the activation of the transcription 
factor sterol responsive element binding protein-lc (SREBP-lc) and hepatic steatosis in a 
fructose-fed mouse model (Zhang et al. 2012).
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Figure 1-3 - Overview of the M am m alian Unfoided Protein Response.
GRP78, activation of PERK, IREla, and ATF6 are released following accumulation of 
unfolded proteins leading to attenuation of protein translation and activation of gene 
transcription (Pagliassotti 2012).
The UPR is activated under ER-stress by the ER-proteins inositol-requiring l a  (IREla), PERK, 
and activating transcription factor 6 (ATF6), which associate with 78 kDa glucose-regulated 
protein (GRP78) permitting the GRP78-complex to sequester unfolded proteins. The 
activated protein complexes can also influence activation of inflammatory mediators such 
as JNK, TNFa and necrosis factor kappa B (NFkB), leading to increased inflammation, IR and 
apoptosis (Zhang & Kaufman 2008). Stimulation of the UPR exacerbates the development 
of hepatic steatosis in NAFLD because IREla modifies hepatocyte lipogenesis through 
interaction with X-box-binding protein 1 (XBPl) (Ning et al. 2011) in insulin-mediated 
hepatic lipogenesis. It is speculated that PERK may alter lipogenesis through its interaction 
with p-elF2a (Bobrovnikova-Marjon et al. 2008), while ATF6a may decrease the regulatory 
cleavage and maturation of SREBP2 at the ER lumen (Zeng et al. 2004).
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1.2.6 Intestinal Bacterial Overgrowth
Inappropriate intestinal bacterial overgrowth is associated with obesity, NAFLD and NASH 
(Ley et al. 2005, Wigg et al. 2001). Small intestinal bacterial overgrowth can lead to 
increased levels of TNFa, and thus promote IR and a pro-inflammatory state. Intestinal 
permeability correiates with hepatic steatosis in patients with histologicaily confirmed 
NAFLD, but not NASH (Mieie et al. 2007). A major consequence of small intestinal bacterial 
overgrowth is that Iipopoiysaccharide (LPS) derived from gram-negative bacterial cell walls 
activates inflammatory cytokine expression by interaction with Toll-like receptor-4 (TLR-4) 
in the inflammatory cells of the liver (Abu-Shanab 2010). Activation of TLR-4 triggers 
intracellular activation of JNK and NFkB and interferon regulatory factor 3 (IRF-3). NFkB 
then directs the expression of the inflammatory cytokines TNFa, and IL-1 and 6 (Abu- 
Shanab 2010). R-4-null mice showed that knockout of TLR-4 afforded protection from the 
development of hepatic steatosis and NASH following treatm ent with a methionine-choline 
deficient diet (Rivera et ai. 2007), and from high-fructose feeding (Spruss et al. 2009). 
Human patients with histologically confirmed NAFLD and NASH have also shown raised 
levels of endotoxins when compared to control patients, in addition to IR (Harte et al. 
2010).
Dietary fructose treatm ent in mice led to increased hepatic steatosis and greater portal 
blood LPS and TNFa levels than glucose-treated control animals (Bergheim et al. 2008). 
These effects of fructose were attenuated by co-treatment with antibiotics. Human studies 
also report association between fructose intake, blood LPS level, hepatic TLR-4 expression 
and NAFLD (Thuy et al. 2008).
1.3 Treatment Strategies for Non-Alcoholic Fatty Liver Disease
There is not yet an agreed strategy for treatm ent of NAFLD and NASH. The criteria for
gauging the effectiveness of a treatm ent regime include improvement to the level of 
steatosis and resolution of indications of NASH, such as the inflammation and cytologic 
ballooning that are associated with fibrosis progression . There are several possible routes 
for pharmacological treatm ent to address NAFLD/NASH, including the use of insulin 
sensitisers such as the biguanide metformin, and the thiazoladinediones pioglitozone or 
rosiglitazone.
Improved diet and lifestyle modification have been shown to improve insuiin resistance, a 
key feature of the NASH risk factors (Zivkovic et al. 2007). Adoption of cognitive
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behavioural therapy and smartphone interactive support programs can enhance patient 
compliance and improve clinical outcomes for NAFLD (Centis et al. 2013).
1.3.1 Weight Loss Ameliorates Non-Alcoholic Fatty Liver Disease
NAFLD patients have been shown to have a higher energy intake in comparison with
healthy controls (Capristo et al. 2005). The combination of both a dietary intervention and 
the introduction of physical activity were assessed in 31 NASH patients (Promrat et al. 
2010). The patients were assigned into a control group, and received information about 
lifestyle modification, or an intervention group, which received an energy-controlled diet, 
with limited fat content and specific physical activity goals. Liver biopsies were repeated 
after 1 year. The intervention group had an average weight-ioss of 9.3% bodyweight, 
compared to 0.2% in the control group, and made significant improvements to the NAFLD- 
activity score (NAS). In particular, those in the intervention group that lost at least 7% of 
their bodyweight had significant histological improvements such as decreased hepatic 
steatosis, lobular formation and hepatocyte ballooning, but not of fibrosis. In the UK, 
clinical practice nutrition and activity guidelines have been shown to be effective at 
reducing hepatic steatosis in 10 obese patients with hepatic steatosis, with evidence of 
reduction in whole-body adiposity, as well as decreased liver and intramuscular lipid 
content and improvements to liver function tests (Thomas et al. 2006). Treatment 
consisted of regular appointments with a registered dietician, with the goal of a gradual 5- 
10% loss of bodyweight over 6 months through a 500 kcal/d energy deficit, using 3-day 
diaries of food intakes and activity logs.
1.3.2 Antioxidant Vitamins
There is a particular focus on the antioxidant vitamin E and its potential usefulness in 
decreasing oxidative stress as part of NAFLD treatm ent. In a pilot study, vitamin E 
decreased iipid peroxidation products, markers of oxidative stress and inflammation and 
the extent of fibrosis in paediatric NASH patients when administered as a dietary 
supplement (Lavine 2000). Examination of dietary records suggests that NASH patients 
have a lower dietary intake of vitamin E (Musso et al. 2003). Vitamin E was recently shown 
to improve liver histology in the PIVENS randomized controlled trial of pioglitazone or high- 
dose (800 lU/day) vitamin E for nonalcoholic steatohepatitis in 247 NASH patients over 96 
weeks (Sanyal et al. 2010). However, IR was not improved by vitamin E and neither was 
fibrosis. Combination of high dose vitamin E and vitamin C (1000 lU/day each) therapy over 
6 months resulted in a modest improvement of fibrosis in NASH patients compared to 
samples from patients taking a placebo (Harrison et al. 2003). By using samples collected
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during the recent PIVENS study, baseline metabolomic profiles were analysed to identify 
those patients that could respond to vitamin E treatm ent and end-of-treatm ent profiles 
that showed a histologic improvement (Cheng et al. 2012). This approach identified that 
histologic response to vitamin E treatm ent was directly associated with baseline levels of 
phenyl-propionic acid and indole-propionic acid levels, indicating that the metabolic profile 
of study subjects who were responsive to vitamin E treatm ent for NASH differ from non­
responders.
The recent 96 week TONIC randomised controlled trial was to determine whether NAFLD 
improved in 57 8-17 year-old children treated with 1000 mg metformin, or with 800 lU 
vitamin E therapy in 58 8-17 year-old children (Lavine et al. 2011). There were 58 control 
patients receiving placebo medication. Investigators chose a 50% reduction in the ALT 
serum level in comparison to baseline measurement as the primary outcome measure, 
with the option of considering ALT results of 40 U/L or less at patient visits during the latter 
half of the study to have met the criterion for the primary outcome also. Secondary 
outcome measures considered were improvements to NAFLD histological features and 
resolution of NASH. It was found that a sustained fall in ALT level during the study was 
similar between the placebo group and both the vitamin E and metformin groups, leading 
to the conclusion that neither vitamin E nor metformin were better than placebo with 
respect to producing a sustained fall in ALT level in paediatric NAFLD patients. There were 
greater reductions in the hepatocellular ballooning and the NAFLD activity scores with 
vitamin E treatm ent in comparison to metformin treatm ent, both of which demonstrated a 
larger reductions in these secondary outcome measures than did placebo. Of those study 
subjects with NASH, resolution of NASH at 96 weeks was greater with vitamin E treatm ent 
than with placebo or metformin, and metformin yielded greater NASH resolution than 
placebo. It is not clear why ALT level was selected as a primary outcome measure, given 
that liver function test results may not necessarily reflect liver abnormality (Browning et al.
2004).
1.3.3 Dietary Fat and Non-Alcoholic Fatty Liver Disease
A high-fat diet (>37% of energy) has been suggested as an independent risk-factor for the  
development of NAFLD and its progression to NASH (Sathiaraj et al. 2011, Vilar et al. 2008). 
It has recently been shown that patients with NAFLD consume more SFA, and few er 
polyunsaturated fatty acids (PUFA), less dietary fibre, and that their diets have a lower 
antioxidant content (Zelber-Sagi et al. 2007, Musso et al. 2003). MUFA-rich diets 
(frequently referred-to as Mediterranean diets, and ranging from 25% to 35% fat, (W illet et
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al, 1995)) have been associated with anti-inflammatory and cardiovascular benefits for 
cardiovascular disease and metabolic syndrome in epidemiological studies (Gillingham et 
al. 2011, Martinez-Gonzalez & Sanchez-Villegas 2004). In particular, a diet that featured 
olive oil was shown to decrease TAG accumulation within the liver, and muted postprandial 
triglyceride and glucose production in patients with IR (Assy et al. 2009). MUFA from olive 
oil were found to decrease NFkB activation, decrease oxidation of LDL, and improve IR by 
decreasing the production of TNFa and IL-6, in addition to decreasing the phosphorylation 
of IRS-1 byJNK.
Fish oils are an excellent source of the n-3 PUFAs eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), and these n-3 PUFAs are known to exert protective effects on 
NAFLD and its associated clinical features (Di Minno et al. 2012). Western diets are skewed 
towards excessive n-6 PUFA consumption over n-3, and lower intakes of n-3 PUFAs can lead 
to hepatic steatosis resulting from increased de novo lipogenesis and fatty acid uptake, 
with decreased fatty acid oxidation (Araya et al. 2004). Recently, administration of n-3 
PUFAs (1.0 or 2.0 g/day for 6 to 12 months) was shown to improve hepatic steatosis, 
inflammation, and blood lipids in patients with NAFLD in pilot studies. 12 months of 
supplementation with Ig  n-3 PUFA per day led to significant decreases in serum AST, ALT 
and GGT (P= 0.003, 0.002 and 0.03 respectively), serum TAG (P=0.02) and fasting glucose 
(P=0.02) in 42 NAFLD patients relative to 14 controls with NAFLD, along with significant 
improvement to liver ultrasonography (P=0.0001) (Capanni et al. 2006). In another study 
(Spadaro et al. 2008), 20 NAFLD patients consumed the American Heart Association 
recommended diet plus 2g per day of n-3 PUFA over 6 months, and were compared to a 
control group of 20 NAFLD patients just consuming the standard diet. This treatm ent group 
displayed significant decreases in serum ALT (P<0.01) and TAG (P<0.01), and TNFa (P<0.05), 
with improved HOMA (IR) (P<0.05) relative to the untreated group. Also although both 
groups exhibited improved liver fat content (assessed by ultrasound), the n-3 PUFA treated  
group displayed complete regression of fatty liver in 33% of patients, with an overall 
reduction of liver fat in 50%. In contrast, only 27% of NAFLD patients receiving the standard 
diet had a reduction of liver fat, with no change observed in the remaining control patients.
1.3.4 Manipulation of Carbohydrate Intake
A eucaloric, low-fat, high-carbohydrate diet is known to promote increased de novo fatty  
acid synthesis (Hudgins et al. 1996). A study of two groups of NAFLD patients compared the  
effects an energy-restricted diet of between 1,200 to 1,500 kcaI/day depending on 
bodyweight and a diet that limited carbohydrate intake to 20 g/day (Browning et al. 2011).
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Similar weight-loss was recorded in both groups of NAFLD patients, and the weight loss 
resulted in a reduction in hepatic fat as measured by magnetic resonance spectroscopy. 
Those NAFLD patients following the low-carbohydrate diet experienced a more 
pronounced decrease in hepatic triglyceride level (55%) compared with the patients 
following the energy-restricted diet (55% vs.28%; P=0.008). Another study in 22 obese 
patients with MRI-confirmed hepatic steatosis compared the effects of an 1100 kca I/day 
diet that was either high or low in carbohydrate (Kirk et al. 2009). A differential effect of 
low-carbohydrate low-energy diet was observed in comparison to a high-carbohydrate low- 
energy diet: the low-carbohydrate group led to significantly greater reductions of 
intrahepatic fat (29.6% vs 8.9%; P < 0.05 determined by MRI).
1.3.5 Dietary Fructose
Fructose is almost entirely metabolised within the liver. Initial studies of hepatic fructose 
metabolism identified that fructose metabolism can perturb hepatic carbohydrate and lipid 
metabolism because of the by-pass of fructose away from normal glycolytic metabolism 
(Mayes 1993). This leads to rapid increases in pyruvate and lactate available for 
biosynthesis, and a diversion of NEFA away from oxidation towards estérification to TAG. 
There is also an acute fall in hepatic adenosine triphosphate (ATP) owing the rapid 
phosphorylation of fructose to fructose-l-phosphate (FIP) by fructokinase. A key feature of 
hepatic fructose metabolism is that this rate-1 imiting-step is not subject to regulation with 
respect to the hepatocyte's energy status (ATP and citrate levels), in contrast to glycolytic 
metabolism of glucose.
Excessive consumption of soft drinks has been linked to body weight-gain, increased 
markers of metabolic syndrome, and type-11 diabetes (Schulze et al. 2004). Dietary fructose- 
consumption has been identified as a risk factor for NAFLD (Ouyang et al. 2008). 
Assessment of biopsy-proven NAFLD severity and self-reported fructose consumption 
beverages showed that NAFLD patients consumed more fructose in the form of high 
fructose corn syrup (MFCS) or from sugar-sweetened beverages (Ouyang et al. 2008). These 
NAFLD patients also showed increased serum cholesterol and plasma uric acid levels 
compared to non-NAFLD control subjects. Real-time PCR of liver samples indicated an 
increased mRNA expression of ketohexokinase (KHK), fatty acid synthase (FAS) and 
xanthine dehydrogenase compared with controls, and although only KHK and FAS were  
significantly increased, this would be consistent with adaptive upregulation of enzyme 
expression in response to chronic fructose consumption. More recent research has shown 
that NAFLD severity is correlated with fructose intake. For example (Abdelmalek et al.
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2010), an investigation into the extent or severity of disease in 427 NAFLD patients in 
comparison to their dietary fructose consumption (as estimated from the Block food 
questionnaire) found an association of fructose intake with metabolic and histological 
features of NAFLD. After controlling for confounding factors in younger adults, daily 
fructose consumption was associated with a lower steatosis grade and a higher fibrosis 
stage. In adults older than 48 years of age, daily fructose consumption was associated with 
increased inflammation and histological ballooning of hepatocytes.
Increased sustained isocaloric substitution of fructose for glucose in overweight or obese 
male and female volunteers for a period of 10 weeks (where participant energy needs were 
met but not exceeded, and that fructose or glucose-only drinks contributed 25% of total 
diet energy), resulted in distinct physiological differences between the two cohorts, despite 
similar bodyweight gains (Stanhope et al. 2009). Fructose-treated participants displayed 
increased VAT volume (an increase of >20 cm3). Despite fasting plasma TAG only increasing 
for the glucose-treated group after 10 weeks, the fructose treated subjects had increased 
hepatic DNL (glucose-treated: 21% ± 9% vs. fructose-treated: 104% ± 19% x 16 h; P = 
0.0043) and plasma triglycerides in the 23-hour period following fructose administration. 
Fructose, but not glucose, treated participants also had 17% decreased insulin sensitivity as 
assessed by deuterated glucose disposal (Stanhope, Schwarz et al. 2009). Further 
investigation (Cox et al. 2012) of the participant energy expenditure and substrate 
utilization as assessed by indirect calorimetry revealed that the fructose-consuming group 
developed significant decreases of net postprandial fat oxidation and significant increases 
of net postprandial carbohydrate oxidation following 10 weeks of dietary intervention 
(P<0.0001 for both), as well as a decrease in total energy expenditure (P=0.031). These 
differences at 10 weeks compared to the initial values were not found in the glucose­
consuming group.
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Figure 1-4 - Liver Fructose Metabolism and Its Relationship to Glucose and Lipid 
Metabolism.
(From Mayes, 1993) Pase; phosphatase, P; phosphate.
Dietary interventions have been studied to investigate the effects of decreasing fructose 
intake in NAFLD patients. A small 6-month dietary study in 15 NAFLD patients showed that 
decreasing dietary fructose content by half significantly reduced hepatic lipid content, 
plasma ALT and AST levels, and improve patient body mass index (BMI) and fasting plasma 
insulin level (Volynets et al. 2013).
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1.4 Use of Human Hepatocyte Cell Lines for the Investigation of 
Lipid Overload and Pathogenic Mechanisms in Non-Alcoholic 
Fatty Liver Disease
As discussed in section 1.2.1, oversupply of free fatty acids to hepatocytes resulting in lipid
accumulation is considered the "first-hit" in the progression of NAFLD (Day & James 1998). 
The respective fates of specific fatty acids and the metabolic consequences constitute the 
"second-hits" that lead to the progression of NAFLD to NASH (Day & James 1998, Charlton
2007). Radioisotope studies of lipid metabolism in obese subjects with NAFLD (Donnelly et 
al. 2005) showed that 67% of NEFA that enter the liver originate from dietary sources or 
from insulin-resistant VAT. Approximately 26% of NEFAs are generated through 
upregulated DNL within the liver (Donnelly et al. 2005). In vitro models for the 
characterisation of lipid oversupply to the liver frequently utilise immortalised human 
hepatocytes and have been used primarily for studies of fatty acid treatments upon lipid 
content. The main human hepatoma cell lines that have been used to investigate lipid 
treatm ent are HuH7 and HepG2 (Malhi et al. 2006, Malhi 2008, Gao et al. 2012, Choi et al.
2011, Cui et al. 2010, Dashti & Wolfbauer 1987, Dashti et al. 1989, Gomez-Lechon et al. 
2007, Joshi-Barve et al. 2007, Jung et al. 2012, Lee et al. 2010, Liu et al. 2011, Luo et al.
2012, Meex et al. 2011, Pullinger et al. 1989, Ricchi et al. 2009, Srivastava 2008, W att et al. 
2012, Wu et al. 2012, Zhang et al. 2010, reviewed by Chavez-Tapia et al. 2011).
1.4.1 Studies of Palmitic Acid and Oleic Acid Oversupply to Human Hepatocyte 
Cell Lines
In HepG2 cells, the fatty acids palmitic acid (PA) and oleic acid (DA) exhibited differential 
cytotoxic and apoptotic characteristics (Ricchi et al. 2009). Treatment of cells with a 2:1 
ratio of DA over PA for 24h ameliorated the potently toxic and apoptotic effects observed 
during administration of a 2:1 ratio of PA relative to OA over 24h, using 0.66 mM or 1.32 
mM OA and 0.33 mM or 0.66 mM PA. The consequence to the treated HepG2 cells of PA 
treatm ent was lipid accumulation and cytotoxicity. In Hep G2 cells (Srivastava & Chan
2008), treatm ent with 0.7 mM PA was followed by a significant rise in the oxidation of free 
fatty acids when measured by radiolabelling. Inhibition of (3-oxidation by using 100 pM  
etomoxir increased free fatty acid toxicity as measured by lactate dehydrogenase (LDH) 
release. PA or OA treatm ent also resulted in lipid accumulation and altered amino acid 
metabolism, and an enhancement of de novo ceramide synthesis, as assessed by metabolic 
flux analysis. Moreover, treatm ent with 0.7 mM PA lead to a fall in cysteine-transporter
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xCT-mediated uptake of cysteine, resulting in diminished glutathione production, indicative 
of compromised antioxidant status (Srivastava & Chan 2008).
Initially, the use of OA oversupply was for studies of the regulation of apoB/VLDL 
expression and secretion (Dashti & Wolfbauer 1987, Dashti et al. 1989). Exposing HepG2 
cells to different ratios of PA to OA (1:2) resulted in varying lipid accumulation dependent 
on dose, ratio and length of exposure to fatty acids (Ricchi et al. 2009). PA alone, at 0.33 
mM and 0.66 mM, was associated with a significant rise in PPARa expression over 24h, 
while 0.66 m M and 1.32 m M  OA alone was associated with a significant rise in PPARy 
expression. The 1.32 m M OA also increased SREBP-1 expression, while the effect of an 
equal mixture of OA:PA had no significant effect. PA disrupted the downstream signalling of 
the hepatocyte insulin receptor mediator Akt, indicating that PA can decrease hepatocyte 
insulin sensitivity (Ricchi et al. 2009). Quantification of gene expression in an OA-induced 
HepG2 lipid accumulation model (Cui et al. 2010) showed that OA increased the expression 
of PPARa, as well as that of TNF-a as OA concentration was increased from 0.1 m M to 2.0 
m M. OA-induced expression of PPARa was also associated with reduced (3-oxidation and 
increased lipid peroxides, while OA-treatment also decreased HepG2 superoxide 
dismutase-1 expression (Cui et al. 2010). The authors concluded that OA acid treatm ent 
induced inflammation and lipid peroxidation, while also limiting p-oxidation of the fatty  
acid burden and diminishing a major component in antioxidant defence in HepG2 cells.
1.4.2 Inflammation and Apoptosis
PA treatm ent of HepG2 cells has been shown to stimulate the production of certain pro- 
inflammatory cytokines. For instance, the proinflammatory cytokine IL-8 was upregulated 
in response to PA treatm ent of HepG2 cells at pathophysiologically relevant concentrations 
of up to 400 |iM  (Joshi-Barve et al. 2007). This increased secretion of IL8 in steatotic HepG2 
was due to stimulation of IL-8 expression by NF-kB and JNKl. In another example (Choi et 
al. 2011), the activity of the inflammatory mediator visfatin in modulating the PA-induced 
upregulation of the proinflammatory cytokines IL-6 and TNFa mRNA expression in HepG2 
cells was also found to result from the action of NFkB in response to PA treatm ent (0, 250 
and 500 pM over 24h or 48h) in a time and dose-dependent manner. Short-interfering-RNA  
(siRNA) inhibition of visfatin lead to significant decrease in IL6 and TNFa mRNA expression, 
while pharmacological inhibition of NFkB or use of adenoviral-lxBa could reduce the 
expression of visfatin despite PA exposure. More, the mechanism by which the n-3
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polyunsaturated fatty acid DHA was able to prevent and reverse NASH in vivo was 
investigated in HepG2 cells (Luo et al. 2012). HepG2 cells were treated with a range of PA 
doses (0, 200 and 400 pM ) with or without preincubation with 50pM  DHA. DHA- 
preincubation significantly ameliorated the PA-induced lipid accumulation and the  
secretion of the inflammatory factors IL-IB, IL-18, TNFa and monocyte chemoattractant 
protein-1 (M CPl). DHA also diminished the PA-induced mRNA upregulation of the HepG2 
inflammasome protein NLRC4, and could partially abrogate the NLRC4-mediated activation 
of caspase-1 and the maturation of IL-IB by PA. Furthermore, PA oversupplied to HepG2 
cells was shown to be incorporated into newly synthesised ceramide, which was then 
secreted in a time and dose-dependent manner (W att et al. 2012). Since the expression 
and activity of the rate-limiting enzyme in the de novo synthesis of ceramide, serine C- 
palmitoyltransferase, was not correlated with ceramide synthesis or secretion, it is likely 
that ceramide synthesis in HepG2 is driven by the availability of substrate (PA), indicating 
another route by which PA treatm ent can also increase signalling to induce apoptotic 
mechanisms. This would concur with the finding of an enhancement of de novo ceramide 
synthesis upon PA-treatment of HepG2 by Srivastava and Chan (Srivastava & Chan 2008).
1.4.3 Insulin Resistance
As discussed above (sections 1.1.1, 1.2.1) IR is a key component of the pathophysiological 
mechanism of NAFLD (Donnelly et al. 2005). Fatty acid treatments may contribute towards 
the development of IR in in vitro models in various ways, such as oxidative stress (Gao et al. 
2010); the induction of NFkB leading to ER stress and stimulation of pro-inflammatory 
cytokines such as TNFa (Lee et al. 2010); and the initiation of the UPR (Cao et al. 2012). The 
contribution of PA to induce IR may occur partly by oxidative stress, and the production of 
ROS stemming from oxidative stress following PA treatm ent may be mediated through the  
activity of the enzyme NADPH-Oxidase-3 (N0X3) (Gao et al. 2010). PA-treated HepG2 cells 
had upregulation of NOX-3, and of inducers of TNFa such as JNK and p38 MAPK, the  
upregulation of which could be attenuated by siRNA-inhibition of N0X3, which also 
resulted in a diminished production of ROS.
OA, but not PA, was shown to induce lipid accumulation in HepG2 cells confirmed by oil 
red-0 staining and Nile Red quantification (Lee et al. 2010). It was also found that OA, but 
not PA, activated the maturation of the lipogenic transcription factor SREBPl. PA was 
shown to induce ER-stress via JNK activation and protein kinase B (PKB) inactivation, to
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decrease Ser-473 phosphorylation of the insulin signalling mediator Akt, leading to 
inactivation of Akt. PA also increased HepG2 cell DAG concentration without altering the 
concentration of ceramide, which led to an increase in the activity of protein kinase C-e 
(PKCe). OA was not found to enhance JNK activation, or to change the activation of the 
mediator of insulin signalling Akt. Instead of increasing DAG concentration, OA led to 
increased TAG concentration (confirmed by lipid stains), and there was no OA-driven 
change in the activation of PKCs. These data suggested a mechanism of PA-mediated 
lipotoxicity that led to IR due to the direct inactivation of insulin signalling mediators by a 
selective partitioning of PA towards DAG synthesis which was concluded to lead to 
inactivation of the insulin receptor by activation of the IkKB and/or NFkB pathway by PKCe. 
PKCe has previously been shown to be activated by DAG in other in vitro models (Nagle et 
al. 2007, Itani et al. 2002).
In another study (Wu et al. 2012), treatm ent of HepG2, Huh7 human hepatocytes and 
mouse primary hepatocytes with OA was also shown to increase lipid accumulation in 
these hepatocytes without diminishing the insulin sensitivity of the cells, further 
highlighting the differential effects of OA on the development hepatocyte IR in comparison 
to PA. The maintenance of insulin sensitivity in the face of OA treatment-induced lipid 
accumulation was found to be because of OA significantly increasing the expression of 
PPAR6 by means of a calcium-dependent pathway (Wu et al. 2012). OA also induced the 
expression of another protein, G-protein-coupled receptor 40 (GPR40), which when 
inhibited by siRNA attenuated the effect of OA upon PPAR5 expression, increasing the 
steatotic effect of OA while permitting the development of IR.
Investigation of the effect of PA in HepG2 cells to induce ER stress indicated that PA 
treatm ent increased the phosphorylation of PERK, and the subsequent expression of the 
UPR mediators BiP, ATF4 and CHOP (Cao et al. 2012). siRNA silencing of PERK with PERK 
short hairpin RNA (shRNA) suppressed the action of this signalling pathway in response to 
PA-treatment, and lead to a significant reduction of apoptosis in HepG2 cells. In another 
study (Achard & Laybutt, 2012), although incubation of HepG2 cells with PA could be 
shown to induce the UPR in a dose dependent manner when the dosing was acute, with a 
low-level of PA pre-incubation HepG2 cells only displayed an attenuated ER stress response 
following an acute high dose PA challenge, indicating that chronic low-level ER-stress from  
a lower dose of PA may have an adaptive effect. This was confirmed by assessment of
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insulin-stimulation of Akt phosphorylation, with the lower-level PA pre-treated HepG2 cells 
demonstrating an augmented phosphorylation of Akt upon high-dose PA exposure. 
W ithout the adaptation to chronic ER-stress from PA, the result of severe ER-stress from  
high-dose PA exposure was a greater upregulation of UPR signalling that lead to a 
diminution of insulin sensitivity (Achard & Laybutt, 2012).
The effect of PA to induce cytotoxic cell death was shown to be enhanced synergistically in 
HepG2 cells by co-administration of the G-protein coupled receptor second messenger 
cyclic-adenosine monophosphate (cAMP) (Zhang et al. 2010). Addition of cAMP to PA- 
treated HepG2 cells increased mitochondrial fragmentation and ROS-production. The 
mitochondrial fragmentation permitted the release of mitochondrial proteins that promote 
cytotoxicity such as Smac, leading to activation of caspases that mediate apoptosis (Zhang 
et al. 2010).
1.5 Investigation of Da Novo Lipogenesis and the Regulation of 
Hepatic Energy Metabolism in Hepatoma Cells and Primary 
Hepatocytes
Mammalian global energy balance is strongly determined by the regulation of hepatic 
energy metabolism, due to the liver's pivotal role in carbohydrate and triglyceride synthesis 
(Poupeau & Postic 2011, Postic et al. 2007). Although the acute regulation of hepatic 
glycolytic and lipogenic enzyme activities is subject to allosteric feedback and covalent 
modifications due to substrate availability, the control of glycolytic, gluconeogenic and 
lipogenic enzyme synthesis depends more upon dietary status, in which glucose availability 
has the greatest influence (Dentin et al. 2005, Postic et al. 2007, Poupeau & Postic 2011). 
Insulin acts as the major stimulus of hepatic lipogenesis via the transcription factor SREBP- 
Ic  (Dentin et al. 2005). Glucose further modifies hepatic lipogenic and glycolytic enzyme 
expression via the transcription factor carbohydrate responsive element binding protein 
(ChREBP) (Dentin et al. 2005). ChREBP binds to carbohydrate responsive elements (ChOREs) 
within the promoter regions upstream from target genes for glycolytic, lipogenic and 
gluconeogenic enzymes (lizuka & Horikawa 2008, Uyeda & Repa 2006). The transactivation 
and nuclear translocation of ChREBP involves dephosphorylation of specific serine and 
threonine residues on ChREBP such that it disassociates from the regulatory molecule 14-3- 
3, and can instead form a heterodimer with Max-like protein-X (Mix) (Cairo et al. 2001,
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Stoeckman et al. 2004). The fed state leads to a rise in xyllulose-5-phosphate (X5P) from  
the hexose monophosphate shunt and this stimulates the activity of protein phosphatase 
2A (PP2A) to dephosphorylate ChREBP (Kabashima et al. 2003). In the fasted state, the 
activities of protein kinase A and AMP-activated protein kinase serve to phosphorylate 
ChREBP and induce its binding to 14-3-3 and sequestration out of the nucleus (Kawaguchi 
et al. 2002, Kawaguchi et al. 2001). Though the nuclear translocation and activity of ChREBP 
is determined by glucose, the transcription and expression of ChREBP proteins in primary 
hamster hepatocytes and HepG2 human hepatocytes was recently found to be regulated 
by insulin (Sirek et al. 2009). Insulin removed the effects of the repressor proteins Pit-1, 
O ct-l/O ct-2 , and Unc-86 (collectively abbreviated to "POU") that bind to the ChREBP 
promoter region. Removal of the ChREBP POU-promoter region prevented insulin-driven 
up-regulation of ChREBP mRNA transcription. This dependence of ChREBP expression upon 
insulin stimulus prior to any activation of mature ChREBP (by glucose) to promote the 
expression of enzymes for DNL may be relevant to design of studies for the testing of 
lipogenic stimulus of carbohydrates in human hepatocytes.
1.5.1 HepGZ Studies of Hormonal and Carbohydrate-Regulation of Lipogenic 
Enzymes
The respective roles of glucocorticoids and insulin upon the transcriptional activity of the 
acetyl-CoA carboxylase (ACC) isoenzymes were recently studied in HepG2 cells (Zhao et al. 
2010). Both insulin and glucocorticoid hormones stimulated the three promoters for ACC 
(termed PI, PM, and Pill), and use of both hormones together had an additive effect on the 
activity of PI and Pll (though not on Pill). SREBP-lc in particular stimulated all three of the  
ACC promoter sequences, while the transcription factor Liver X-Receptors a/|3 (LXRa/(3) 
were more specific; LXRa only increased transcriptional activity in response to hormonal 
stimulus at the ACCl Pll site, while LXR(3 only exerted a minimal hormone-driven stimulus 
at any ACC promoter, as did ChREBP. These findings tell us that the pivotal lipogenic 
enzyme ACC is regulated predominantly by insulin stimulus via SREBPlc binding to its 
promoters, with LXRa playing only a minor role. Hormonal modification held little influence 
over the binding of ChREBP to ACC promoter sequences. Earlier efforts (Semenkovich et al. 
1993) to clarify the varying extents to which hormones and glucose regulated fatty acid 
synthesis in HepG2 cells examined the effects of varying physiological glucose 
concentrations in hormone and serum-free culture media upon fatty acid synthase (FAS) 
expression. Elevated D-glucose concentrations stimulated the expression of FAS mRNA 
from 2.7 to 5.4-fold in a time-dependent manner, while other lipogenic substrates such as
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lactate and citrate but not L-glucose also stimulated FAS mRNA expression. Use of 
cyclohexamide and puromycin demonstrated that the stimulatory effects of glucose on FAS 
mRNA expression are due mostly to a bolstering of FAS mRNA stability, rather than by any 
alteration of the initiation of transcription.
1.5.2 Effects of Fructose in Human Hepatocytes
Some of the key differences between hepatoma cell and hepatocyte fructose metabolism 
have been investigated by comparing HepG2 cells with primary hepatocytes (Speicher et al. 
2010). The selective nature of the effects of hepatocyte transformation to a malignant 
state were demonstrated in HepG2 cells. When treated with fructose, HepG2 cells did not 
undergo a transient depletion of ATP, in contrast to primary mouse hepatocytes. This 
absence of ATP-depletion by fructose in hepatoma cells is due to over-expression of 
hexokinase II (HKII), which alters the hepatoma cell fructose metabolism from liver-type to 
muscle-type. The increased expression of HKII prevents the normal action of fructokinase 
to phosphorylate fructose to FIP, using ATP in the process. The consequence of this is that 
hepatoma cells are not afforded cytoprotection from TNFa-mediated apoptosis due to the 
failure of fructose to deplete ATP reserves, making the hepatoma cells selectively 
susceptible to immunotherapeutic approaches that do not target naïve hepatocytes that 
have normal fructose metabolism.
The results of different approaches to investigate fructose metabolism and lipogenesis or 
lipid accumulation using HepG2 cells have been equivocal. Fructose has been shown to 
alter the stimulatory effect of glucose upon the expression of ACC; and to the deactivate 
the-phosphorylation of HSL and also that of adipose triglyceride lipase (ATGL) in HepG2 and 
mouse primary hepatocytes (Huang et al. 2011). This modification of glucose lipogenic 
stimulus by fructose was shown to lead to increased de novo TAG synthesis in the in vitro 
models, but only demonstrated an increase of hepatocyte lipid accumulation (steatosis) in 
an in vivo fructose-feeding model (Huang et al. 2011). Interestingly, the experimental 
procedures for the cell culture denote that the HepG2 cells were grown until only 30% 
confluent and were then subject to overnight incubation in glucose-free Dulbecco's 
modified Eagle's medium (DMEM) with 5% foetal bovine serum (FBS), prior to 72 h 
treatments and co-treatment with glucose(5.5 or 11.1 m M ) and/or fructose (0.55 or 5.5 
m M) (Huang et al. 2011). A critical weakness of this study is that although lipid 
accumulation is shown by Oil Red-0 staining, there is no quantification of the intracellular
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TAG in HepG2. Despite evidence of production of secondary metabolite (FIP) from fructose 
by HepG2 cells over 24 h, another group (Hirahatake et al. 2011) failed to demonstrate an 
effect of 5 m M fructose with 5.5m M  glucose upon the alteration of expression of the 
lipogenic enzymes ACC and FAS over 24h, 48h or 72h compared to control conditions (5.5 
mM glucose). Again, it is unfortunate that this study also did not provide quantification of 
HepG2 intracellular TAG. HepG2 cells were cultured with 5.5 mM glucose minimal essential 
medium (MEM) with 10% (v/v) FBS until cells reached 80% confluence, at which point MEM  
without sera was used for treatments.
In contrast to these studies, an earlier investigation (Collison et al. 2009) of the effects of 
high fructose corn syrup (HFCS-55) upon intracellular TAG content, lipogenic gene 
expression and mitochondrial function found that in sufficient quantity, HFCS-55 mixed into 
cell culture media could significantly alter these aspects of HepG2 cell function in a dose- 
dependent fashion. Exposure to fructose and glucose monomers from HFCS-55 lead to a 
non-linear rise in intracellular TAG, as shown by Sudan Black staining and enzymatic 
quantification. The expression of the lipogenic enzyme ACC was increased. Similar dosing 
with sucrose or glucose alone did not elicit such effects. HFCS-55 treatm ent increased the 
HepG2 cytochrome c release to cytosol, indicating mitochondrial damage. In addition, basal 
production of ROS, and a diminished the capacity of the cells to accommodate an oxidative 
challenge, were further evidence of effects of mitochondrial damage. Other effects 
included activation of JNK and down-regulated insulin signalling in response to 100 nM  
insulin. Two features of this study are of particular interest; the 0-2.5% (v/v) doing range of 
HFCS-55 equates to a supraphysiological maximal dose of 135 mM of combined hexose 
monomers, and the treatments were performed in culture media with FBS present. 
Overnight culture in serum-free media was only utilised prior to investigations of how 
responsive the cells were to insulin treatm ent.
1.5.3 GLUT Expression in HepGZ
There is uncertainty over whether hepatoma cell lines, including HepG2, express sufficient 
levels of the carbohydrate transport proteins GLUT2 and GLUTS, such that fructose may be 
able to gain access to the cell for metabolism. Early comparison of HepG2 GLUT2 
localisation with that from rat hepatocytes (Hah et al. 1992) revealed that HepG2 GLUTl 
and GLUT2 had different sub-cellular distributions, with GLUT2 mainly found intracellularly 
associated with microsomes, GLUTl was absent from this subcellular location. Insulin
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treatm ent did not alter the localisation of GLUT2 from within the cell in either HepG2 or rat 
hepatocytes. In a more recent study, a positive correlation was shown in HepG2 cells 
between the overexpression of GLUTl mRNA and protein and 2-[18F]-2-deoxy-D-glucose 
((18)F-FDG) uptake into cells (R^=0.88, P<0.001), as measured by positron emission 
tomography (Ong et al. 2008). In contrast to these reports, a study of the inhibitory effects 
of phloretin on GLUT activity, reported that in HepG2 cells, GLUT2 showed a high level of 
activity localised at the cell membranes (Wu et al. 2009). Phloretin-induced apoptosis 
correlated with GLUT2 expression. Quantitative comparison of GLUT transcript copy 
number (per beta-actin) in HepG2 versus human liver (Takanaga et al. 2008) indicated that 
GLUTl had 107 transcripts compared with 0.836 per beta-actin in HepG2 and human liver 
respectively. GLUT2 expressed only 3.98 transcripts per beta-actin in HepG2, compared 
with 54.6 transcripts per beta-actin in human liver. This would suggest a gross reversal of 
naïve hepatocyte GLUT 1 and GLUT2 transcript expression in HepG2. No data was available 
for the expression of GLUT5 in either HepG2 or human liver cells. Since mRNA transcript 
expression is not necessarily reflective of protein expression, siRNA interference of GLUT 
expression was used to identify the effects of individual GLUT expression on overall glucose 
flux: only GLUTl and GLUT9 inhibition caused a significant decrease to glucose-flux, 
consistent with their over-expression in HepG2. With conflicting reports, it is difficult to  
conclusively surmise that HepG2 cells definitely do or do not express GLUT2 and GLUT5 
hexose transporters sufficiently for adequate uptake of fructose from culture media.
1.5.4 Use of Primary Hepatocyte Cultures for Study of Carbohydrate and Lipid 
Metabolism
Primary mouse or rat hepatocytes have proven to be an important and valuable tool for 
research into hepatic metabolism and nutrition, pharmacology and toxicology. When 
correctly isolated, the relatively short lifespan of primary mouse or rat hepatocytes is 
contrasted by the tremendous experimental utility they offer a researcher in terms of the  
breadth of assays that may be performed on them. Initially, research using ex vivo liver 
tissue made use of hepatocytes isolated by mechanical means, such as disruption or finely 
slicing liver tissue, though these early efforts had the considerable disadvantage of causing 
inadvertent mechanical damage to the desired hepatocytes before any experimental work 
could be performed. These issues were partially circumvented by Berry and Friend in the  
1960s (Berry & Friend 1969) with their introduction of collagenase-based digestion of liver 
tissue. Subsequently, Seglen (1976) improved upon this development by making use of the  
highly vascular state of the whole liver for perfusion-based isolation of hepatocytes in
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calcium-free buffer before collagenase digestion of the collagen extracellular matrix. When 
using a variant of the two-step perfusion method for isolating primary hepatocytes, the 
researcher must take great care to work quickly and cause the minimum of mechanical 
disruption to the cells as is possible. Once isolated, the viability of primary hepatocytes 
must be confirmed by visual inspection to ensure that the cells display a sufficient trypan 
blue exclusion yield before continuing to use a preparation of freshly isolated hepatocytes 
for subsequent experimental work.
1.5.5 Primary Hepatocyte Studies of De Novo Lipogenesis
Over the years, mouse or rat primary hepatocytes have served as useful in vitro model 
systems for the basis of investigations into the hormonal and nutritional factors that 
regulate the expression and activities of the individual enzymes that comprise de novo 
lipogenesis pathway (ATP-citrate lyase, acetyl CoA-carboxylase, fatty acid synthase and 
stearoyl CoA-desaturase, abbreviated to ACL; ACC; FAS and SCD-1, depicted in Figure 1.5 
below). More recently, primary hepatocyte culture systems have also been utilised to 
investigate the regulation of the expression and activity of the chief regulatory 
transcription factors that control expression of lipogenic ACL was studied in rat primary 
hepatocyte cultures (Katz & Giffhorn 1983). ACL action between 24h and 48 hours in 
culture could be elevated by 1.5-fold using an insulin concentration of 10-7mol and by 1.22- 
fold by raising media glucose concentration from 5 to 25 mM. A 3.5-fold rise was achieved 
by simultaneously elevating insulin and glucose concentrations. These changes in ACL 
activity were ablated by interrupting enzyme protein synthesis with cyclohexamide.
ACC activity was shown in primary rat hepatocyte cultures (Giffhorn & Katz 1984) to be 
independently regulated by either glucose or insulin, with a multiplicative effect of raising 
the culture media concentration of both. Again, in another study (Spence et al. 1985) the  
increased activity was found to be due to an increased rate of enzyme synthesis due to 
increased transcription, without any difference in the rate of degradation of the enzyme. 
Stimulation of ACCactivity by insulin was also found to occur initially before changes in 
protein synthesis, suggesting additional post-translational regulation.ChREBP and SREBP­
lc .
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Figure 1-5 - De Novo Lipogenesis.
(from Uyeda & Repa, 2006). ACL: ATP citrate lyase; ACC: acetyl CoA carboxylase; FAS: fatty  
acid synthase; SCDl: stearoyl CoA desaturase. ChREBP: carbohydrate responsive element 
binding protein.
Separately, fructose-addition without insulin was able to raise ACC-activity 3-fold (Fukuda 
et al. 1992), whereas addition of glucose alone had no effect, unless insulin was also added. 
Another investigation (Salati & Clarke 1986) of the effects of combinations of hormones in 
controlling lipogenesis in primary rat hepatocyte cultures showed that lipogenesis could be 
induced threefold by the combination of insulin and dexamethasone, and that increased 
fatty acid synthesis was paralleled by increased synthesis of ACC. Dexamethasone was 
found in this study to be required for the action of insulin upon ACC activity. The inclusion 
of 0.2 mM fatty acids in the culture media could modestly suppress the induction of ACC by 
insulin and dexamethasone co-treatment. Co-treatment of rat primary hepatocytes with 
insulin and triiodothyronine enhanced the induction of the lipogenic enzymes (Fukuda et al. 
1992). In a subsequent study, the stimulatory effects of insulin, dexamethasone, 
triiodothyronine, and glucose, and the inhibitory effect of PUFA to regulate the expression
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of the ACC gene were partly found to occur via the ACC PI promoter (O'Callaghan et al. 
2001, Kim et al. 2005).
Investigation in primary hepatocytes from female rats (Giffhorn-Katz & Katz 1986) showed 
that culture at low glucose concentrations (5.5 mM) with 0.5 nM insulin resulted in a 
gradual fall in FAS activity over the course of the culture period. Use of 100 nM insulin 
slightly ameliorated the diminution of FAS activity, while use of 20 m M  glucose lead to a 3- 
fold increase in FAS activity over that of the basal conditions. Simultaneous use of 20m M  
glucose with lOOnM insulin caused an 8-fold rise in FAS activity over 5 days. Inhibition of 
hepatocyte glycolysis prevented the enhancement of FAS activity, suggesting that the  
regulatory mechanism for FAS is controlled by a glucose metabolite. The increase in FAS 
activity was due to increased protein synthesis and a fall in the rate of FAS protein 
degradation. In subsequent studies (Hansmannel et al. 2006, Magana et al. 2000), the 
stimulatory effect of insulin upon FAS was shown to be due to the action of SREBP-lc 
recruitment to the FAS promoter. Further work (Prip-Buus et al. 1995) using cultures of 
primary hepatocytes from suckling rats found a requirement for glucokinase activity and 
the production of the glycolytic metabolite glucose-6-phosphate in order for FAS mRNA 
expression to be induced, and (Mourrieras et al. 1997) that the stimulatory actions of 
insulin, dexamethasone and triiodothyronine on FAS induction were in part due to the  
hormones ability to stimulate glucose phosphorylation.
A 90h study of rat primary hepatocyte SCD-1 (Legrand & Bensadoun 1991) found that the  
enzyme activity fell by half over the first 40h of cell culture without hormonal treatments, 
after which it would remain constant. SCD-1 activity was subject to stimulation by 
treatm ent of primary hepatocytes by insulin, but remained constant upon administration of 
dexamethasone or triiodothyronine. Replacement of culture media glucose with fructose 
could enhance SCD-1 activity, however prior starvation followed by sucrose re-feeding of 
donor-rats did not affect the SCD-1 activity of the subsequently cultured hepatocytes. 
Primary cultures of chicken hepatocytes (Legrand et al. 1994) confirmed the stimulatory 
effect of insulin upon SCD-1 shown in rat hepatocytes, and that 0.5M  linoleic acid could 
suppress the action of SCD-1. The stimulatory effects of insulin and the inhibitory effects of 
glucagon upon SCD-1 activity (Lefevre et al. 1999) were found to be due to effects on SCD-1 
transcription and mRNA stability, with the inhibition by glucagon being greater than that of 
the stimulatory effect of an equivalent dose of insulin. Increased expression and activity of
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SCD-1 was also found to "desaturate" saturated fatty acids within mouse primary 
hepatocytes via their conversion to mono-unsaturated fatty acids (Benhamed et al. 2012). 
This was shown to cause a beneficial fall in the overall lipotoxicity that impinged on the 
cells. This fall in lipotoxicity protected insulin sensitivity, and thus had the effect of 
dissociating primary hepatocyte lipid accumulation from IR.
1.5.6 Regulation of Activity of Carbohydrate Responsive Element Binding 
Protein (ChREBP)
ChREBP acts to direct hepatocyte de novo lipogenesis in response to regulation by glucose 
(Benhamed et al. 2012). The carbohydrate responsive element (ChoRE) for liver-type 
pyruvate kinase (L-PK) was first characterised in rat liver tissue (Yamashita et al. 2001), and 
it was found that high carbohydrate diet induced the binding of ChREBP to the L-PK ChoRE. 
Over-expression of ChREBP in rat primary hepatocytes activated L-PK in response to  
glucose via phosphorylation of the DNA-binding motif of ChREBP (Yamashita et al. 2001). 
ChREBP binding to the ChoRE requires the formation of a heterodimer with Max-like 
protein-X (Mix) (Stoeckman et al. 2004). In addition to this, ChREBP and hepatocyte nuclear 
factor-4 (HNF-4) together co-ordinately regulate the glucose-induction of FAS in primary rat 
hepatocytes (Adamson et al. 2006). The transcription of ChREBP mRNA in primary hamster 
hepatocytes is regulated by insulin (Sirek et al. 2009). Removal of the ChREBP POU- 
promoter region prevented insulin-driven up-regulation of ChREBP mRNA transcription. In 
addition to stimulating lipogenesis, it has been shown in primary hepatocytes, that ChREBP, 
via the mediator regulator-of-G-protein-signalling (RGS16), also acts to inhibit the 13- 
oxidation of fatty acids within the hepatocyte (Pashkov et al. 2011).
1.5.7 Regulation of Activity of Sterol Responsive Element Binding Protein-lc  
(SREBP-lc)
In rat primary hepatocytes (Deng et al. 2002), transient transfection of a cloned 1.5-kb 
sequence upstream from the SREBP-lc start site ligated to a luciferase reporter sequence 
was used to demonstrate the stimulatory role of insulin in activating the promoter, 
irrespective of a low or high media glucose concentration. The stimulation of the reporter 
by insulin was subject to inhibition by both dibutyryl-cAMP and various PUFA; however, the 
monounsaturate OA and the saturated fat PA were not effective at inhibiting the insulin- 
stimulation of the reporter. A 149-bp segment of the 1.5-kb sequence was found to contain 
several sterol responsive elements (Deng et al. 2002). In another primary hepatocyte study 
of the regulation of lipogenic gene expression by SREBP-lc (Kohan et al. 2011), the
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inhibitory effect of PUFA delivered by chylomicron remnants has also recently been 
demonstrated, and contrasts that of non-esterified PUFA in that PUFA delivered by 
chylomicron remnants did not inhibit the accumulation of mRNA for malic enzyme, 
glucokinase, or L-PK. This suggests that the means of delivery of non-esterified PUFA to 
primary hepatocyte cultures must be considered when interpreting how PUFA regulate 
lipogenic gene expression in cultured hepatocytes.
The role of the transcription factor FOXOl in regulating the insulin-stimulus of SREBP-lc co­
ordination of expression of lipogenic enzymes has been more clearly defined in primary 
hepatocytes (Deng et al. 2012). A constitutively active form of FOXOl prevented the 
stimulation of the SREBP-lc promoter by insulin. Chromatin immunoprécipitation (ChIP) 
assay of the SREBP promoter region revealed the association there of FOXOl and the  
ensuing disruption of the formation of a functional transcriptional complex needed for the  
initiation of SREBP-lc expression. W e could surmise from these studies that the expression 
of SREBP-lc is stimulated by insulin, inhibited by non-esterified PUFA, and is modified by 
FOXOl.
Stimulation of insulin signalling by a high-carbohydrate diet fed to rats promoted the 
transcription of SREBP-lc in vivo (Stoeckman & Towle 2002). Over-expression of SREBP-lc 
in primary hepatocytes only modestly increased the mRNA-expression of FAS and ACC, 
when compared to the inducing-effect of insulin and glucose treatm ent. Addition of insulin 
to SREBP-lc-overexpressing primary hepatocytes lead to no further increase in the 
induction of FAS or ACC mRNAs relative to control hepatocytes that expressed normal 
levels of SREBP-lc, suggesting that insulin and glucose exert greater influence over the  
action of SREBPlc to promote FAS and ACC (Stoeckman & Towle 2002). Two sterol- 
responsive elements were identified in the promoter region of liver glucokinase, and the  
binding of SREBP-lc with these sequences was confirmed in vivo (Kim, Kim et al. 2004), and 
in subsequently isolated primary hepatocytes, insulin increased the expression of SREBP-lc 
and glucokinase in vitro. Use of adenoviral overexpression of SREBP-lc also increased the 
expression of glucokinase, while overexpression of a double-null SREBP-lc variant 
prevented the increase in expression of glucokinase by insulin and SREBP-lc, indicating that 
stimulation of glucokinase expression by insulin is dependent on the action of SREBPlc 
(Kim, Kim et al. 2004). Another study (Yellaturu et al. 2005) showed that in rat primary 
hepatocytes, the post-translational processing of SREBPla and SREBPlc isoform proteins
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from their precursor peptides was stimulated by insulin within 1 hour of addition, and this 
maintained the post-translational processing maintained for a further 24 h. This post- 
translational processing was inhibited by dibutyryl-cAMP. Another study in primary 
hepatocytes (Im et al. 2005) indicated that transcription of the GLUT2 promoter was 
stimulated by the binding of SREBP-lc, and that adenoviral overexpression of a dominant- 
null form of SREBP-lc failed to stimulate GLUT2 induction in response to glucose, 
suggesting a dependence on SREBPlc.
Since SREBP-lc is activated by insulin, activation of SREBP-lc under conditions of IR would 
seem paradoxical. The molecular chaperone glucose responsive protein 78 (GRP78) 
suggests a link between ER stress and the stimulation of SREBP-lc cleavage and activation, 
despite IR (Kammoun et al. 2009). ER stress was induced in primary hepatocyte cultures 
from IR ob/ob mice by exposure of the cells to compounds known to induce ER-stress (such 
as thapsigargin, which modifies ER lumen Ca^  ^ concentration; and tunicamycin and 
homocysteine, which inhibit protein glycosylation or the formation of disulphide bridges, 
interrupting the process of protein maturation within the ER, leading to accumulation of 
proteins within the ER lumen). ER stress and the inducement of the UPR were confirmed 
through measurement of expression of the spliced form of X-box binding protein-1 (XBPl) 
mRNA. Adenoviral overexpression of GRP78 in primary hepatocyte cultures inhibited both 
the insulin-dependent and ER-stress-induced cleavage of immature SREBP-lc from SREBP- 
cleavage-activating-protein (SCAP) (confirmed by western blot), and the subsequent 
expression of the target genes of the mature form of SREBP-lc (for example, glucokinase). 
In vivo, an ob/ob mouse model also demonstrated the effect of adenoviral over expression 
of GRP78 upon SREBP-lc induction under conditions of ER stress, with a decreased level of 
lipogenesis in ob/ob mouse livers and the amelioration of both the intracellular TAG and 
cholesterol contents (confirmed by oil red-0), as well as the re-instatement of insulin 
sensitivity (Kammoun et al. 2009). The UPR also influences SREBP-lc-mediated lipogenesis 
via the IREa-XBPl signalling pathway (Pagliassotti 2012). Under conditions of IR, the IR El-a- 
XBPl pathway is activated by ER stress and the UPR (Ning et al. 2011). This was shown in 
primary culture, by overexpression of XBPl which upregulated SREBP-lc and FAS, while 
knockdown of IREl-a or XBPl inhibited the effect of insulin to stimulate SREBP-lc and FAS 
induction. The direct interaction between XBP-1 and SREBP-lc promoter was confirmed by 
Chip assay, and XBPl-stimulus of FAS could be prevented by knockdown of SREBP-lc (Ning 
et al. 2011).
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1.5.8 Primary Hepatocyte Cultures Investigating Triacylglycerol-Synthesis and 
Lipolysis
Hepatic free fatty acids must be incorporated into glycerolipid to produce intracellular TAG 
within lipid droplets. Mitochondrial glycerophosphate acyltransferase (mtGPAT) catalyses 
the initial and rate-limiting step of formation of TAG (Wendel et al. 2009). The pivotal role 
that liver mtGPAT holds in the regulation of hepatic glycerolipid synthesis was 
demonstrated (Linden et al. 2004) by adenoviral-overexpression of murine mtGPAT in rat 
primary hepatocyte cultures, resulting in a 2.7-fold rise in mtGPAT activity and an 80% 
reduction of mitochondrial beta-oxidation of fatty acids. In addition, DAG and phospholipid 
concentrations were also increased, and lipid-treatment of mtGPAT-overexpressing 
primary hepatocytes caused greater accumulation of intracellular TAG than in control cells. 
Primary hepatocyte cultures have also been useful for investigating the effects of DAG and 
altered expression of diacylglycerol acyltransferase (DGAT). While antisense- 
oligonucleotide (ASO)-interference of DGAT2 expression decreased in vivo hepatic steatosis 
in high-fat diet-induced obese mice (Yu et al. 2005), ASO-interference of DGATl in primary 
hepatocytes isolated from methionine-choline deficient (MCD)-diet fed mice indicated that 
DGATl-inhibition had no effect on hepatocyte intracellular TAG content, but did diminish 
hepatic stellate cell activation, and collagen formation, while increasing hepatic stellate cell 
vitamin-A retention (Yamaguchi et al. 2008). This suggests that DGAT2 exerts more 
influence over hepatic intracellular TAG content. PNPLA3 has single nucleotide 
polymorphisms (SNPs) associated with an increased risk of hepatic steatosis and NAFLD in 
humans (Li et al. 2012). ChIP and electrophoretic mobility-shift (EMSA) assays of mouse 
livers confirmed SREBP-binding to sterol responsive elements (SREs) in the promoter 
regions of PNPLA3 (Qiao et al. 2011). Overexpression of PNPLA3 in primary hepatocyte 
culture lead to increased intracellular TAG content, while PNPLA3 knockdown led to a 
suppression of SREBP-lc-mediated stimulus of TAG-synthesis and accumulation. Together, 
these studies suggest how pivotal acyl transferase activities are in the formation of TAG 
from fatty acids, potentially leading to steatosis.
1.5.9 Lipid-Treatments of Primary Hepatocyte Cultures
Treatment of primary rat hepatocytes with free fatty acids showed (Patsch et al. 1983) that 
while the intracellular stores of TAG increased dramatically, and the size of exported 
lipoproteins increased, the amount of apolipoproteins secreted remained unchanged by 
increased fatty acid. Treatment of cultured hepatocytes for 12h with free fatty acids 
followed by analyses of cells and media at 8h and 22h after the loading period showed that
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intracellular TAG content was directly correlated with free fatty acid treatm ent 
concentration, and that over the period after cessation of treatm ent, the rate of secretion 
of apolipoproteins was dependent on the intracellular TAG mass following the treatm ent. 
Further demonstration of the role of fatty acid availability on the rate of incorporation of 
fatty acids into intracellular TAG mass was provided by a primary hepatocyte model tested 
by Chambaz and co-workers (Chambaz et al. 1986). The rate of uptake of fatty acids was 
governed by the availability of albumin-bound fatty acids, rather than of free-fatty acids. 
The type of fatty acids did not affect the rate of uptake, and the composition of fatty acids 
in intracellular TAG reflected that of the fatty acids bound to albumin in the treatm ent 
media.
Salati and Clarke (1986) used insulin and dexamethasone to stimulate lipogenesis by ACC in 
primary rat hepatocytes, and these hormone treatments led to a 3-fold induction of ACC 
activity. Dexamethasone was found to be required for the lipogenic stimulus of insulin 
upon ACC. The effects of 0.2m M  of various free fatty acid co-treatments to hormone- 
stimulated primary hepatocytes were suppression of the insulin/dexamethasone 
stimulated increase in ACC activity by approximately one third, irrespective of the chain 
length or degree of saturation of the fatty acid used (Salati & Clarke 1986). Although 
treatm ent of these primary hepatocytes with O.SmM of linoleic acid did not result in any 
greater suppression of ACC activity relative to 0.2 mM linoleic acid, the use of O.SmM PA 
resulted in a greater suppression of ACC activity and depletion of the hepatocyte ATP 
content (Salati & Clarke 1986). Another study (Hennes, Shrago et al. 1990) performed in 
hepatocytes isolated from 12-week old female rats, the effects of 0-2.0 mM PA treatments 
on the binding and action of insulin to the insulin receptor was investigated. The primary 
fate of PA under such conditions was found to be p-oxidation, rather than incorporation 
into intracellular TAG. Increasing concentrations of PA treatments diminished the cell- 
surface binding of insulin to the insulin receptor. This was found to be due to a decrease in 
the number of insulin receptors at the cell surface in response to PA-treatments. There was 
a non-linear diminution of the extent of internalisation and degradation of insulin bound to 
the cell-surface insulin receptor, this decrease of receptor internalisation was 
disproportionately greater at higher PA treatm ent concentrations, but the effect was 
reversed at the highest PA treatm ent (Hennes et al. 1990).
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Treatment of primary rat hepatocytes for 20h with 0.5 m M PA subsequently led to a 
differential impairment of the effects of insulin (Galbo, 2011). Although the 
phosphorylation of insulin receptors in response to insulin was not affected by PA 
treatm ent, the downstream activation of Akt was curtailed, with consequential failure to 
activate the Akt targets glycogen synthase kinase 3a, glycogen synthase, indicating that 
under PA treatm ent, insulin stimulation of the oxidation of glucose and the synthesis of 
glycogen by primary hepatocytes were impaired. PA treatm ent also attenuated the 
inactivation of the transcription factor FOXOl by Akt, resulting in continued expression of 
gluconeogenic genes despite insulin stimulus. However, despite the above effects of PA 
treatm ent to impair insulin-mediated FOXOl regulation by Akt, PA treatm ent of primary 
hepatocytes did not hinder the insulin stimulus of DNL, TAG assembly or of TAG 
accumulation. It was found by specific inhibition of atypical PKCs during PA treatm ent that 
the insulin stimulation of DNL and TAG synthesis could be prevented, indicating that the 
effects of PA treatm ent upon insulin stimulus occur via atypical PKCs. Atypical PKCs have 
been implicated in another PA-treatment model in HepG2 (Lee et al. 2010).
In another study (Malhi et al. 2006), SFA were found to induce greater activation of JNK and 
of apoptosis relative to MUFA in mouse primary hepatocytes, an effect which was 
ameliorated by pharmacological inhibition of JNK. Saturated fat induction of JNK activated 
caspases, and cytochrome c release from mitochondria, which was preceded by 
mitochondrial membrane depolarisation. The lipoapoptotic activation of JNK leading to this 
mitochondrial damage from saturated fat treatm ent was shown by siRNA knockdown to 
occur via the proapoptotic Bcl2 mediators Bim and Bax (Malhi et al. 2006). Further studies 
in hepatoma cells and primary mouse hepatocytes indicated that lipid accumulation from  
OA could induce the activation JNK and death receptor 5 (DR5), leading to the sensitisation 
of hepatocytes to the action of TNF-related apoptosis-inducing ligand (TRAIL) (Malhi et al. 
2007). Also, treatm ent of hepatoma and primary hepatocytes with SFA indicated that 
mitochondrial damage could be driven by the activation of the lysosomal protein Cathepsin 
B (Li et al. 2008).
1.5.10 Summary and Research Aims:
Human hepatocytes have been used to investigate various aspects of NAFLD 
pathophysiology, in particular the effects of PA and OA treatments upon hepatocyte IR, ER 
stress and the mechanisms of the UPR. The nutritional and hormonal regulation of DNL via
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the transcription factors ChREBP and SREBPlc have also been examined in human 
hepatocytes. It is unclear whether human hepatocyte models uniformly express the GLUT2 
hexose transporter that would be required for entry of fructose into cells. Metabolism of 
fructose has been demonstrated in HepG2 cells, although the overexpression of HK-II may 
subvert fructolysis in these cells from liver-type to muscle-type. The potential for fructose 
and glucose treatments to increase DNL and the expression of the enzymes for DNL has 
been shown in some studies, but further work is required to confirm the effects of fructose 
and glucose treatments in human hepatocyte models.
Primary hepatocytes have provided useful data on aspects of the hormonal and nutritional 
control of the expression and activity of the various enzymes that perform DNL and of the 
regulation of expression and action the transcription factors SREBPlc and ChREBP that 
moderate DNL enzyme expression. Lipogenesis in primary hepatocyte cultures is subject to 
adequate background hormonal stimulus as well as nutritional stimulus from glucose. 
Treatment with fatty acids may inhibit DNL in primary hepatocytes, and stimulates 
activation of inflammation and apoptosis. ER stress and the UPR also influence the action of 
SREBPlc and its role in lipogenesis. PA treatm ent of human hepatocytes and mouse or rat 
primary hepatocytes has been found to exert cytotoxic effects, increase de novo synthesis 
of ceramide and stimulate apoptosis. PA treatm ent led to IR via the activation of atypical 
PKCs, as well as induction of inflammation and the expression of proinflammatory 
cytokines, which were ameliorated by OA. PA treatm ent has also led to stimulation of the 
NFkB pathway and induction of ER stress and the UPR. OA treatments of human 
hepatocytes and mouse or rat primary hepatocytes have demonstrated lipid accumulation 
and stimulation of the expression of TNFa and PPAR5. OA treatments have not been shown 
to lead to IR in hepatocytes, nor to increase ceramide production or to induce ER stress or 
the UPR. Although glucose has been shown to stimulate the expression and activity of DNL 
in primary hepatocyte models, the effects of fructose have not been so well established.
Research Aims & Hypothesis:
The aims of this project were to establish a robust in vitro model of hepatocyte lipid 
accumulation, and then to test the effects of fructose challenge upon the lipid content of 
the hepatocytes. It is hypothesised that treatm ent of HepG2 human hepatocytes with  
increasing concentrations of fructose would cause an increase in the lipid content of the 
hepatocytes, reflecting the hepatic lipid accumulation observed in NAFLD.
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2 Use o f Human Hepatocytes for the Investigation o f Lipid- 
Overload in Non-Alcoholic Fatty Liver D isease
2.1 Introduction
As described in Chapter 1, the by-pass of fructose metabolism away from glycolytic 
metabolism means that fructose can perturb normal hepatic carbohydrate and lipid 
metabolism (Mayes 1993). In humans, soft drink consumption is associated with increased 
body weight and the development of metabolic syndrome and T2D (Schulze, et al. 2004), 
and increased dietary fructose intakes have been identified as a risk factor for NAFLD 
(Ouyang, et al. 2008), and were associated with NAFLD severity (Abdelmalek, et al. 2010). 
Other research has shown that 10 week isocaloric substitution of fructose for glucose lead 
to an increase in hepatic DNL and plasma TAG following fructose administration (Stanhope, 
et al. 2009), along with a decrease in total energy expenditure and net post-prandial fat 
oxidation (Cox, et al. 2012). A 6 month reduction of dietary fructose intake was found to 
decrease intrahepatic fat content (Volynets, et al. 2013).
A considerable number of recent human hepatocyte models have been published in which 
the lipid content of the cells was increased as a result of treating the cells with different 
concentrations of lipids such as PA or OA, or PA;OA mixtures (Chavez-Tapia, et al. 2011). In 
vitro studies of fructose treatm ent of FiepG2 human hepatocytes have yielded equivocal 
results. Fructose has been shown to be metabolised in HepG2 (Speicher, et al. 2010, Huang, 
et al. 2011, Hirahatake, et al. 2011), and fructose has been shown to modify the lipogenic 
stimulus of glucose in HepG2 cells, but was only shown to increase oil red-0 lipid staining of 
HepG2 cells as opposed to showing a quantified increase of HepG2 cell TAG (Huang, et al. 
2011, Hirahatake, et al. 2011). In contrast to this result, high dose HFCS treatm ent of 
HepG2 cells was shown to increase HepG2 intracellular TAG content quantitatively, 
although the HFCS treatments were made in the presence of culture media FBS (Collison, et 
al. 2009).
The aim of the experiments detailed in this chapter was to assess quantitatively the effect 
of fructose treatments on the intracellular TAG content of HepG2 cells, and to quantify the 
effects of fructose treatm ent on HepG2 cells viability.
2.2 Materials & Methods
2.2.1 Reagents
HepG2 cells were sourced from European Collection of Cell Cultures (ECCAC). Eagle's 
Minimal Essential Medium (EMEM) with 5.5 mM glucose, Dulbecco's Modified Essential
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Medium (DMEM) with 5.5 m M glucose, and DMEM with 25 mM glucose were sourced from  
Lonza (Lonza, Wokingham, UK). Non-essential amino acids (NEAA) lOOX, 2 mM L- 
Glutamine, lOX trypsin in ethylene diamine tetra actetic acid (EDTA) and heat-inactivated 
FBS were also obtained from Lonza. PA, OA and fatty-acid-free bovine serum albumin (FAF- 
BSA) obtained from Sigma (Sigma, Poole, UK). Stock Oil Red-0 and the serum triglyceride 
determination kit (TROlOO) were also from Sigma. Quantitation of sample protein content 
was by the BCA protein assay from Pierce. Quantitative assessment of cell viability was 
done using the Pro mega Cytotox 96 Non-Radioactive Cytotoxicity Assay (Promega, 
Southampton, UK).
2.2.2 Cell Culture of HepG2
HepG2 human hepatocytes were cultured in low-glucose EMEM or DMEM (as indicated) 
with a 10% (v/v) FBS supplement, and 2 m M  L-glutamine, 0.1 mM NEAA and 100 U/ml 
penicillin/streptomycin. Cell culture was at 37°C with 5% O2 . HepG2 ceils were
cultured until approximately 80% confluent, and then detached using IX  trypsin in 
phosphate-buffered saline (PBS), at pH 7.4, counted with a haemocytometer and then 
seeded at 2.0 x 10^ per cm^. The passage window for the HepG2 cells was between 6 and 
27 passages. Cultures were not tested for the presence of mycoplasma.
2.2.3 Collagen -Coating Culture Ware for HepG2 Culture
A 0.1% (w/v) solution of Type I Calf Collagen was purchased from Sigma (product code 
C8919).The desired volume of 0.1% collagen solution was diluted 10-fold in sterile ddh20  
(according to surface area to be treated) to a working concentration of 0.01% (w /v) for 
coating surfaces. Dishes were coated with 8 pg/cm^. The protein was allowed to bind 
overnight at 2 -8  °C. Excess fluid was aspirated from the coated surface, and allowed to dry 
overnight, while being further sterilized by 2h exposure to UV light in a sterile tissue cuiture 
hood. Collagen-coated culture vessels were then rinsed with sterile PBS (pH 7.4) solution 
before introduction of cells and medium.
2.2.4 Fructose and Fructose-Glucose Treatments of HepG2
HepG2 ceils seeded on 6-well culture plates or in T25 vented culture flasks were washed
twice with warmed PBS before treatm ent with serum-free EMEM containing various 
fructose concentrations. Stock 1.0 M fructose-containing EMEM, filtered through 0.22 pm 
pore-size membrane, was used to produce the different fructose treatments in serum-free 
EMEM of 20, 30, 40, 50 or 60 mM fructose with 5.5 mM glucose. Fructose treatm ents were  
for 48h, 72h or 96h. Additionally, subsequent fructose treatments of 25, 50, 75 and 100
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mM were also administered to HepG2 cells in EMEM with 5.5 m M glucose or 60 mM  
glucose over 96h.
2.2.5 Palmitate and Oleate Treatments
HepG2 human hepatocytes seeded on 6 well plates or in 125 vented fiasks were washed 
twice with warmed PBS (pH7.4) before treatm ent with serum-free EMEM or DMEM  
containing various PA or OA concentrations. PA and OA stock solutions (10 m M) were 
produced by separately dissolving PA or OA in dimethyl sulfoxide (DMSO). This 10 mM PA 
or OA stock solution was further diluted to a working solution of 2.5 m M for fatty acid 
treatments by complexing the 10 mM stock solution with 6.67% (w/v) solution of FAF-BSA 
in a ratio of 1:4 (v/v). 6.67% FAF-BSA was produced by dissolving FAF-BSA in double 
distilled (dd) FIzO. Both fatty acidiDMSO and FAF-BSA solutions were separately passed 
through 0.22 pm filters immediately prior to mixture in a sterile tissue culture laminar flow  
hood. The 2.5 mM working solution of PA or OA was further diluted to the desired 
treatm ent concentrations in serum-free EMEM or DMEM as appropriate, using vehicie 
DMSO mixed with 6.67% FAF-BSA (1:4) to ensure that each treatm ent contained the same 
final concentrations of DMSO and FAF-BSA, and that only the treatm ent agent (PA or OA) 
itself varied in concentration. The final concentration of DMSO did not exceed 2% (v/v) for 
any treatm ent. HepG2 celis were treated with either 0 , 50, 100, 150 or 200 pM PA in 5.5 
m M glucose serum-free EMEM; or 0 ,100 , 200, 300 or 400 pM PA in 5.5 mM glucose serum- 
free DMEM, or 0 ,10 0 , 200, 3 00 ,400  or 500 pM OA with 5.5 mM glucose or 25 mM glucose 
DMEM. PA or OA treatments were for 24h prior to trypsin-detachment of hepatocytes.
2.2.6 Oil Red-0 Lipid Staining
At the end of a treatm ent period (48h, 72h or 96h for fructose treatments; 24h for PA or 
OA treatments), treatm ent media was aspirated from HepG2 human hepatocytes or 
mouse primary hepatocytes in 6-well culture plates. The cells were then fixed with 10% 
formalin (3.7% formaldehyde in PBS) for a minimum of Ih  before further preparations. 
Stock Oil Red-0 solution (0.3% (w/v), in propan-2-oi) was diluted 3:2 in ddHzO, mixed by 
vortexing and ieft to stand for 20 min before filtration through 0.45 pm. Formalin was 
aspirated from the fixed cells, which were then washed twice with 60% (v/v) ethanol, 
followed by three separate washes with ddHzO. After washing, cells were dried by 
exposure to air, and also by use of a hairdryer on a 'low' setting to ensure complete drying. 
Diluted Oil Red-0 solution was then used to stain the fixed cells for 10 minutes, after which 
Oil Red-0 was aspirated away to waste, and the now stained cells were further washed 
once more with 60% ethanol, then three more times with ddHzO. The now Oil Red-0
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stained cells were then counterstained with haematoxylin for 4 minutes, and de­
differentiated in 1% acid-alcohol solution for 3-4 seconds, foliowed by a 2 minute rinse 
under gently flowing tap water. If cells were fixed onto microscope covers lips, these were 
then adhered to siides with heated glycerol jelly. After drying, light photomicrographs were 
taken at 400X magnification on a Leica light microscope using the Leica Qwin V3 software 
suite, or at 200X on a Nikon Eclipse TSIOO inverted microscope using NIS Elements 3.0 
software.
2.2.7 Triacylglycerol Assay
HepG2 human hepatocytes were seeded (at 2.0 x 10^ per cm^) into T25 vented culture 
flasks for fructose or fatty acid treatments. Following treatm ent, celis were detached from  
the culture flasks by trypsin-treatment, and then centrifuged at 300g for 5 minutes to form  
pellets. After aspiration of supernatant, the ceil pellets were transferred to 1.5 mL 
microfuge tubes that contained 50 pL of 5% (v/v) Triton X-100 in ddHzO. Samples were 
stored at -20°C for subsequent assay, if required. Samples were prepared to ensure 
complete solubilisation of TAG by three rounds of vortexing, then heating to 80°C for 5 
minutes, following by cooling at room temperature for a further 5 minutes. Then samples 
were sonicated using a probe sonicator (cycle setting of 0.9s, 50% amplitude, Braun 
Biotech) for 10s each. A glycerol standard-curve was produced by dilution of 2.5 mg/mL 
stock glycerol solution in ddHzO, to produce standards of 0.0, 0.2, 0.4, 0.6, 0 .8 ,1 .0 ,1 .2  and
2.5 mg/mL. 2 pL of each standard was pipetted in duplicate into wells of a 96-well 
microplate. Triglyceride assay working reagent was produced by mixing reconstituted Free 
Glycerol and TG component reagents in a 4:1 ratio. A volume of 200 pL of mixed working 
reagent was added to each well, onto either the 2 pL of giycerol standard or sample. After 
10 minutes of incubation at room temperature, absorbance was read at 540 nm using a 
BMG Labtech Omega platereader. In order to normalise the concentrations from the TAG 
assay to cell total protein content, the Pierce BCA assay was performed on samples diluted 
with ddHzO (the dilution factor typicaiiy being 10) so that protein concentrations could be 
compared with the 0.0-2.0mg/mL protein standard curve. This standard curve was made 
using a 2.0 mg/mL BSA stock, serially diluted with ddH20 to produce a range (0.0, 0.125, 
0.25, 0.5, 0 .7 5 ,1 .0 ,1 .5  and 2.0 mg/mL). The BCA kit working reagent was made by mixing 
the reagent A and B components in a 50:1 ratio. A volume of 200 pL of BCA working 
reagent was added to each well (with either 10 pL of standard or of diiuted sample). The 
microplate was then incubated at 37“C for 30 minutes prior to reading absorbance at 
562nm.
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2.2.8 Cell Viability Assay
LDH release to the culture media was used as an indicator of a fall in HepG2 cell viability, 
and is associated with cell apoptotic and necrotic events (Fotakis & Timbrell, 2006). 
Therefore, measurement of culture media LDH content provided information on the 
viability of the cells being cultured. HepG2 cells were seeded at 2.0 x 10"^  per cm^ into Nunc 
6-well plates for fructose or fatty acid treatments. An additional 6-well plate had cells 
seeded for culture in EMEM with and without FBS as well, to allow for comparison with 
treated cells. Culture media was removed in 60 pL aliquots at specified time-points 
foliowing commencement of fructose or fatty acid treatm ent. At the end of the treatm ent 
period, the cells in the additional (untreated) wells were lysed with 30 pL of neat TritonX- 
100 and this media was then sampled to obtain total LDH values with which to compare the 
LDH values from samples obtained from the media of treated ceils. Released LDH in cuiture 
supernatants was measured with a 30-minute coupled enzymatic assay, which results in 
the conversion of a tétrazolium salt (INT) into a red formazan product. The amount of 
colour formed is proportional to the number of lysed cells.
The general chemical reactions of the Promega CytoTox 96® Assay are as follows:
LDH: NAD* + lactate pyruvate + NADH
Diaphorase: NADH + INT NAD* + formazan (red)
Sample absorbance was measured at 540nm and is proportional to the extent of LDH- 
release from cultured cells. Absorbance of culture media with and without the 10% (v/v) 
FBS supplement was also measured in order to assess the effect of sera, and to correct for 
the background absorbance from the cuiture media.
Percentage cytotoxicity is equal to:
Sample abs -  serum-free media abs
Serum-free media total LDH abs - serum-free media abs
2.2.9 Statistical Methods
One-way ANOVA and two-way ANOVA were performed using GraphPad PRISM 6.01  
(GraphPad Software, Inc. USA).
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2.2.10 Summary of Treatments
Treatment
Table 2.1: Fructose Treatments of HepG2 Human Hepatocytes 
Culture Media Time Points Assays Performed Rationaie
0-60 mM Fructose 5 mM Giucose 
EMEM
48, 72, 96 h TAG, LDH Test effect of fructose 
on HepG2
0-100 mM Fructose 
+/- 60 mM Glucose
5 mM Giucose 
EMEM
48, 72, 96 h TAG Test effect of higher 
dose of fructose on 
HepG2, with and 
without giucose
Treatment
Table 2.2: Palmitate Treatments of HepG2 Human Hepatocytes
Assays PerformedCulture Media
Time
Point
Rationaie
0-200 pM PA
0-200 pM PA,
+/- 20 mM Fructose
0-200 pM PA,
+/- coiiagen substratum
0-200 pM PA
5 mM Glucose 
EMEM
5 mM Glucose 
DMEM
5 mM Glucose 
EMEM
5 mM Glucose 
EMEM or DMEM
24 h
24 h
24 h
24h
TAG, LDH, ORO
ORO
ORO
ORO
Test effect of palmitate 
on HepG2
Test effect of paimitate 
on HepG2, +/- fructose
Test effect of paimitate, 
+/- coiiagen
Test effect of palmitate, 
with ceiis grown in 
EMEM or DMEM
Treatment
Tabie 2.3: Oieate Treatments of HepG2 Human Hepatocytes
Time
Assays Performed
Point
Cuiture Media Rationaie
0-500 pM OA
0-500 pM OA
5 mM Giucose 
DMEM, then 
25 mM Giucose 
DMEM
25 mM Giucose 
DMEM
24 h
24 h
TAG, ORO
ORO
Test effect of oleate 
delivered in high- 
giucose media on 
HepG2 grown in low- 
glucose media
Test effect of oieate 
deiivered in high- 
giucose media on 
HepG2 also grown in 
high-giucose media
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2.3 Results
2.3.1 Effects of Fructose Treatment on Intracellular Triacylglycerol in HepG2 
Cells
HepG2 human hepatocytes were treated with increasing concentrations of fructose (0 mM  
to 60 mM) for a treatm ent period of 48h, 72h, or 96h (Figure 2.1). Addition of fructose to 
cell culture media (EMEM with 5 mM glucose) was hypothesised would provide substrate 
for increased synthesis of TAG molecules.. At each of the 48h, 72h and 96h time points, 
there was no relationship between fructose treatm ent (20 mM -  60 mM) and the level of 
intracellular TAG (relative to the total protein content of the samples) as evaluated using 
two-way ANOVA.
300 n
0)  200
O 100 <
96h
30 40
Fructose (m M )
Figure 2-1 -  Effect of Fructose 
Treatment For 48-96h on 
intracellular Triglyceride in HepG2 
Human Hepatocytes.
72h
Intracellular TAG levels of
HepG2 cells exposed to
different concentrations of
fructose (0-60 m M ) for 48h, 
72h or 96h. TAG was measured 
by enzymatic assay and 
normalized to total protein 
content. Data represent mean 
and SD of five independent 
experiments. No significant 
differences w ere found after 
analysis by tw o-w ay ANOVA.
2.3.2 Effect of Fructose Treatment on Cell Viability in HepG2 Human 
Hepatocytes
There was no apparent effect of fructose treatments on LDH from HepG2 cells (Figure 2.2). 
From 48h after the start of fructose treatm ent to the 96h final time point, all fructose 
treatments (0 - 60 m M ) exhibited similar decreases in cell viability as determined from LDH 
release to culture media. Culture media with and without the 10% (v/v) FBS supplement 
were also sampled in order to permit a comparison to samples taken from fructose-treated 
cells. Cell culture media with and without FBS had no apparent effect on HepG2 cell 
viability over the course of 48h to 96h of culture. Additional independent experiments 
would need to be performed in order for a statistical assessment to be robust.
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Figure 2-2 - Treatment With 
Fructose For 48-96h Did Not 
Alter the Decrease of Cell 
Viability in HepG2 Human 
Hepatocytes.
Change in HepG2 
hepatocyte viability after 
treatm ent with different 
concentrations of fructose. 
Data represent mean and 
variation of two  
independent experiments.
Hours after Fructose Treatment
2.3.3 Effect of Fructose and Glucose Co-Treatments on Intracellular 
Triacylglycerol in HepGZ Human Hepatocytes
Since the treatm ent of HepG2 cells with fructose did not elicit detectable intracellular lipid
accumulation, a wider range of fructose concentrations was tested. Treatments of HepGZ 
cells in serum-free EMEM (5 mM glucose) with fructose concentrations ranging from 0-100  
mM also did not alter HepGZ TAG content for treatm ent periods of 48h, 7Zh and 96h. 
Equally, co-treatment with 60 mM glucose in addition to fructose treatments of 0-100 mM  
did not alter HepGZ cell intracellular TAG either (Figure 2.3).
300-,
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Figure 2-3 -  Effect o f Fructose T reatm ent for 96h on Intracellular Triacylglycerol Content In HepGZ 
Human Hepatocytes.
Intracellular TAG levels of HepGZ cells exposed to different concentrations of fructose (O-lOOmM) 
w ithout (A) and with (B) glucose (60m M ) for48h, 72h and 96h. TAG was measured by enzymatic 
assay and normalized to total protein content. Data represent mean and SD of 3 or 4 independent 
experiments. No significant differences were found by two-way ANOVA.
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2.3.4 Effect of Palmitic Acid Treatment on Intracellular Lipid Accumulation in 
HepG2 Human Hepatocytes
Given the apparent failure of fructose treatments to cause lipid accumulation, it was
necessary to establish a positive control for lipid accumulation in HepGZ human 
hepatocytes. HepGZ human hepatocytes were treated in serum-free EMEM with increasing 
concentrations of PA ranging from 50 pM to ZOO pM for a treatm ent period of Z4h. Lipid 
accumulation occurred in a dose-dependent manner (Figure 2.4). Very little lipid 
accumulation was observed in control cells exposed to FAF-BSA with no PA added (Figure
2.4 (A)), in contrast to the higher doses used in this study of 150 pM and ZOO pM PA (Figure
2.4 (D) and (E)), which resulted in extensive formation of large intracellular lipid droplets 
that are characteristic of NAFLD.
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Figure 2-4 - Treatm ent w ith Palmitic Acid For 24h Elicited intracellular Lipid Accumulation 
in HepG2 Human Hepatocytes.
Oil Red-0 staining of HepGZ cells cultured for Z4h in serum-free medium containing either vehicle 
(A) or 50 pM PA (B), 100 pM PA (C), 150 pM  PA (D), and ZOO pM  PA (E). Images were taken using the  
Leica DMLB light microscope with the Leica QWin Software at 400X magnification. Cells were  
counterstained with haematoxylin.
Addition of PA to cell culture media is thought to provide substrate for increased synthesis 
of TAG molecules (Ricchi, et al. Z009). In this example, there was a striking increase in 
intracellular TAG content as PA treatm ent dose was increased (Figure 2.5), quantitatively 
confirming the increasing Oil Red-0 staining observed in the photomicrographs in Figure 
2.4.
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Figure 2-5 - Treatment with Palmitic 
Acid (0-200 pM) for 24h Increased 
Intracellular TAG Content in HepG2 
Human Hepatocytes.
TAG content was measured by 
enzymatic assay and normalized 
to total protein content. Data 
represent mean and SD of three  
technical replicates. P values 
from analysis with one-way 
ANOVA and Dunnet's multiple 
comparison test.
2.3.5 Effect of Palmitic Acid Treatment on Cell Viability in HepG2 Human 
Hepatocytes
LDH-release from HepGZ cells was apparently increased in a dose-dependent manner by PA 
treatm ent. This increased LDH release to the culture media is demonstrates a decrease in 
HepGZ cell viability, and is associated with cell apoptotic and necrotic events.
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Figure 2-6 - Treatment with 
Palmitic Acid (0-200 pM) for 
24h Decreased HepG2
Human Hepatocyte Cell 
Viability.
Data represent mean and 
variation of tw o
independent experiments.
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Time After PalmitateTreatment
24 h
Culture of HepGZ cells with and without FBS had minimal effect on cell viability over the 
course of Z4h of culture. The cell viability of HepGZ cells treated with 50 pM PA was slightly 
lower at all time-points than that of cells undergoing 0 pM treatm ent. Increasing PA 
treatm ent doses (100 pM, 150 pM and ZOO pM) had increasing effects on the progressive 
fall in HepGZ cell viability (Figure 2.6).
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2.3.6 Effect of Further Palmitic Acid Treatments on Intracellular Lipid 
Accumulation in HepG2 Human Hepatocytes
Other work performed using mouse primary hepatocytes (described in Chapter 3) required
the use of a collagen substratum in order for the cells to adhere, and so was used for a 
subsequent cell culture experiment in HepGZ human hepatocytes. In this experiment, the 
hypothesis was that in HepGZ cells seeded onto a collagen substratum, co-treatment of 
ZOmM fructose in addition to the O-ZOO pM PA treatm ent over 24 hours would influence 
lipid accumulation in the cells.
The HepGZ cells were treated in serum-free DMEM for Z4h with O-ZOO pM PA using FAF- 
BSA as vehicle. The overall extent of Oil Red-0 lipid droplet staining was substantially less 
than that observed from the prior experiments. The presence of ZO mM fructose in 
addition to O-ZOO pM PA did not appear to affect lipid accumulation in the HepGZ cells 
(Figure 2.7 (B -F )) .
Oil Red-0 staining of the cells that were fixed at baseline (i.e. that had undergone no 
treatm ent, and thus were just cultured for 7Zh in DMEM with 10% FBS (v/v)) showed 
evidence of lipid staining (Figures 2.7 (A) and 2.8 (A)). However, following the 24 h 
treatm ent period, there was very little discernible Oil Red-0 staining of control cells or cells 
cultured with any of the PA doses (Figures 2.7 (B) -  (F) and 2.8 (B) - (F)). This might suggest 
that Z4h of culture in serum-free media clears intracellular TAG from cells previously 
cultured in low-glucose DMEM with an FBS supplement.
Since much higher levels of TAG/protein were found in the prior experiments in which the 
HepGZ were cultured in EMEM, it was then hypothesised that culture medium may 
influence the results of O-ZOO pM PA treatm ent. For the next HepGZ experiment HepGZ 
cells were passaged in low-glucose EMEM (rather than DMEM) to allow for "reversion" 
from any effects that culture in DMEM may have had upon them.
Oil Red-0 staining confirmed that the cells fixed at baseline had high levels of lipid, based 
upon observable staining. This was the case for both HepGZ cells cultured on normal plastic 
and collagen -coated substrata. For the cells that underwent O-ZOO pM PA treatm ent for 24 
h, there was also no apparent accumulation of lipid droplets regardless of whether they  
had been cultured on a collagen substratum or not (Figure 2.9 and Figure 2.10).
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Figure 2-7 - Treatm ent of HepG2 Cultured in Low-Glucose Dulbecco's M odified Eagle's M ed ium  (5 
m M ) w ith 0-200 p M  Palm itate For 24 Hours.
Oil Red-0 staining of HepG2 cells cultured for 72h with DMEM with 10% (v/v) FBS (A) and treated in 
serum-free DMEM for 24h with 0 pM PA (B), 50 pM PA (C), 100 pM PA (D), 150 pM  PA (E), 200 pM  
(F). Images were taken using the Nikon 1000 light microscope with the NIS-Elements F3.0 Software 
at 200X magnification.
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Figure 2-8 - Treatm ent of HepG2 Cultured in Low-Glucose Dulbecco's M odified  Eagle's M ed ium  (5 
m M ) w ith  0-200 p M  Palm itate and 20 m M  Fructose For 24 Hours.
Oil Red-0 staining of HepG2 cells cultured for 72h with DMEM with 10% (v/v) FBS (A) and treated in 
serum-free DMEM for 24h with 20 m M  fructose and either 0 pM PA (B), 50 pM PA (C), 100 pM  PA 
(D), 150 pM  PA (E),or 200 pM (F). Images w ere taken using the Nikon 1000 light microscope with 
the NIS Elements F3.0 Software at 200X magnification.
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Figure 2-9 - HepG2 Cultured in Low-Glucose (5 m M ) Eagle's M inim al Essential M edium  w ith o ut a 
Collagen Substratum Treated For 24 Hours w ith 0-200 p M  Palm itate.
Oil Red-0 staining of HepGZ cells cultured for 72h with low-glucose EMEM with 10% (v/v) FBS (A) 
and then treated in serum-free low-glucose EMEM for 24h with 0 pM PA (B), 50 pM  PA (C), 100 pM  
PA (D), 150 pM PA (E), or 200 pM (F). Images were taken using the Nikon 1000 microscope with the  
NIS-Elements F3.0 Software at 200X magnification.
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Figure 2-10 - HepG2 Cultured in Low-Glucose (5 m M ) Eagle's M inim al Essential M edium  w ith  a 
Collagen Substratum Treated For 24 Hours w ith  0-200 p M  Palm itate.
Oil Red-0 staining of HepG2 cells cultured for 72h with low-glucose EMEM with 10% (v/v) FBS (A) 
and then treated in serum-free low-glucose EMEM for 24h with 0 pM PA (B), 50 pM  PA (C), 100 pM  
PA (D), 150 pM PA (E), 200 pM  (F). Images were taken using the Nikon 1000 microscope with the  
NIS-Elements F3.0 Software at 200X magnification.
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2.3.7 Further Comparison of EMEM or DMEM Media on the Response of HepGZ 
Cells to Palmitate Treatment
Continued investigation of the treatm ent of HepG2 with 0-200 pM PA in both low-glucose
(5 mM) EMEM and DMEM yielded inconsistent intracellular TAG accumulation in cells that 
had been grown and treated in EMEM (Figure 2.11 (A)), but a two-fold increase in 
intracellular TAG in those that had been grown and treated in DMEM (Figure 2.11 (B)).
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Figure 2-11 - Intracellular Triacylglycerol Content of HepGZ Human Hepatocytes Grown w ith o ut a 
Collagen Substratum in Eagle's M inim al Essential M edium  or Dulbecco's M odified Eagle's M edium .
HepG2 cells were exposed to different concentrations of PA (0-200 pM ) in serum-free EMEM (A) or 
DMEM (B). TAG content was measured by enzymatic assay and normalized to total protein content. 
Data represent mean and SD of 3 independent experiments. P values from analysis with one-way 
ANOVA and Dunnet's multiple comparison test.
2.3.8 Investigation of Effect of Culture Media Glucose Content on Effect of Oleic 
Acid Treatment
W hether culture media glucose content affected the outcome of lipid-overload treatm ent 
was the next variable to be investigated. HepG2 cells were cultured on collagen substratum 
in low-glucose DMEM, and then treated for 24 h with 0-500 pM OA in low-glucose DMEM. 
Visual inspection of oil red-O-staining of the treated HepG2 cells showed an increased 
number of lipid droplets in cells treated with up to 500 pM OA in low-glucose DMEM  
(Figure 2.12), however, there was no apparent difference in the extent of lipid stain 
between cells treated with different levels of OA. This observation was confirmed by assay 
of intracellular TAG and total protein content (Figure 2.13): each OA treatm ent performed 
in high-glucose DMEM resulted in greater intracellular TAG content than for prior PA- 
treatments in low-glucose DMEM (Figure 2.11), but there was still no dose-response trend 
with increasing OA treatm ent concentration from 0-500 pM.
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Figure 2-12 - Culture of HepG2 Human Hepatocytes under Low Glucose Conditions Then Treated  
w ith 0-500 p M  Oleic Acid under High Glucose Conditions.
Oil Red-0 staining of HepG2 cells cultured for 72h in low-glucose DMEM (5 m M ) with 10% (v/v) FBS, 
and then treated in high-glucose (25m M ) serum-free DMEM for 24h at 0 pM OA (A), 100 pM  PA (B), 
200 pM  OA (C), 300 pM OA (D), 400 pM  (E), or 500 pM OA (F). Images were taken using the Nikon 
1000 microscope with the NIS-Elements F3.0 Software at 200X magnification.
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Figure 2-13 - Intracellular TAG in 
HepG2 Human Hepatocytes 
Treated w ith  Oleic Acid.
Cells were grown w ithout a collagen 
substratum in low-glucose DM EM  (5 
m M ) with 10% (v/v) FBS, and then 
treated with different
concentrations of OA (0-500 pM ) in 
serum-free high-glucose (25 m M ) 
DM EM . TAG content was measured 
by enzymatic assay and normalized 
to total protein content. Data 
represent mean of tw o technical 
replicates.
The next passage of HepG2 cells was cultured in high-glucose DMEM prior to another 24h 
of 0-500 pM OA treatm ent in serum-free high-glucose DMEM. There was an apparent 
increase of Oil Red-0 lipid staining as OA treatm ent dose is increased from 0 to 500 pM, 
suggestive of a dose-response (Figure 2.14).
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Figure 2-14 - Culture of HepG2 Human Hepatocytes under High Glucose Conditions Then Treated  
w ith 0-500 pM  Oleic Acid under High Glucose Conditions.
Cell were cultured for 72h in high-glucose DMEM (5 m M ) with 10% (v/v) FBS, and then treated in 
high-glucose (25m M ) serum-free DMEM for 24h at 0 pM OA (A), 100 pM  PA (B), 200 pM  OA (C), 300 
pM OA (D), 400 pM  (E), or 500 pM  OA (F). Images were taken using the Nikon 1000 microscope with  
the NIS-Elements F3.0 Software at 200X magnification.
2.4 Discussion
2.4.1 Lipid Accumulation
The studies described above do not demonstrate that fructose has any effect on HepG2 
cells in terms of lipid accumulation. Culture media glucose concentration was 5.5 mM in all 
of the initial experiments. There was no difference in intracellular TAG in the HepG2 cells 
treated with fructose at concentrations ranging from 0-60 mM. The TAG/protein ratio did 
not exceed 150 pg/mg at any fructose treatm ent concentration at either 48h, 72, or 96h. 
There was considerable variation about the mean for some of the samples and no 
significant differences were found in lipid content following different fructose treatments  
after analysis by two-way ANOVA at any observed time point. Investigation of higher doses 
of fructose (ranging from 0 -  100 mM) confirmed the lack of effect of fructose upon HepG2 
cell intracellular TAG at 48h, 72h and 96h time points. A similar lack of effect was observed 
when this increased dosing range of fructose was combined with supplementary glucose in 
the culture media (60 mM). These results contrast to those from what is currently the only 
published in vitro model (Collison et al. 2009) of lipid accumulation via fructose and glucose 
co-treatment in hepatoma cells. This model used MFCS, mixed directly to the culture media, 
in order to treat the HepG2 cells studied.
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There are several other methodological differences between the current model studied 
here, and the approach used by Collison and co-workers to investigate the effect of 
fructose and/or glucose overload. The current studies test the effect of solely varying 
fructose concentration with constant 5.5m M  glucose concentration, while Collison and co­
workers increased the concentration of both fructose and glucose by mixture of MFCS into 
culture media. If the presence of both fructose and glucose monomers is required for the 
striking increases in intracellular TAG, then the later experiment of co-treating HepG2 with 
25 mM, 50 m M, 75 mM and 100 mM fructose against a background of 60 m M glucose in 
each case should be expected to produce a similar increase in intracellular TAG. As it did 
not, variables other than fructose and/or glucose could be necessary for the increase in 
intracellular TAG by fructose and/or glucose.
Serum-free EMEM was used as the medium for fructose/fructose-glucose treatments in the 
studies described above, while Collison and co-workers used RPMI 1640 with heat- 
inactivated FBS. Collison and co-workers cultured the cells in FBS that had not been heat- 
inactivated, until 50% confluent. At that point the media was changed to include 0.0 -2.5%  
(v/v) MFCS with heat-inactivated FBS at 10% (v/v). Heat-inactivation eliminates mycoplasma 
that are potentially included with FBS, suggesting that mycoplasma contamination in FBS 
that was not heat-treated may have contributed to the discrepancy. FBS is included in cell 
culture for its essential growth factors. It might be possible that heat-inactivated FBS has 
sufficient insulin that, in the presence of high concentrations of hexose, the insulin could 
still stimulate lipogenesis and inhibit ApoBlOO VLDL export in the HepG2 cells, resulting in 
intracellular lipid accumulation. Our HepG2 cells were cultured until 70-80% confluent in 
low-glucose EMEM that had 10% FBS, and then fructose or fructose-glucose treatments 
were delivered in serum-free low-glucose EMEM following two PBS washes to remove any 
trace FBS. If hormonal influence were the necessary factor for driving HepG2 lipid 
accumulation from hexose treatments, then it would be absent from our model and 
perhaps present in that of Collison and co-workers.
Several models of lipid accumulation in hepatoma cell culture have utilised a delivery of 
fatty acids, typically OA or PA, complexed to FAF-BSA (Cui, et al. 2010, Joshi-Barve, et al. 
2007, Lee, et al. 2010, Luo, et al. 2012, Ricchi, et al. 2009, Srivastava & Chan 2008). This 
enables a more precise control of the fatty acid content of the treatm ent media. The 
Collison model may not be controlling for the lipid content of the cell culture media, given 
that it is not clear whether de-lipidated FBS is included in the treatm ent or not. If it were
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the case that de-lipidated FBS was included, then presumably, the effects of MFCS that 
were reported could not be attributed to the presence of lipids in the media (in addition to 
supraphysiological concentrations of fructose and glucose). However, if in fact the heat- 
inactivated FBS used in the Collison HFCS-treatment model also contained an un-quantified 
and unspecified cohort of lipids, then it may be the case that the lipid accumulation 
observed upon treatm ent with 0.0-2.5% MFCS is, at least partly, due to the incorporation of 
these unspecified lipids that had not been controlled for into TAG.
The other experiments detailed here investigating PA and OA treatm ent of HepG2 in 
serum-free EMEM or DMEM were not successful in inducing increased intracellular TAG 
when performed at a low-glucose concentration (5.5 m M). However, by culturing the 
HepG2 cells in 25 m M high-glucose media (for both their growth with 10% FBS and serum- 
free for subsequent OA treatments), then HepG2 lipid accumulation was restored in a 
dose-dependent manner (at least when treated with OA bound to FAF-BSA in serum-free 
high-glucose DMEM). This implies that lipid accumulation in HepG2 cell culture is 
dependent upon an adequate supply of glucose (relative to the specific needs of HepG2) in 
addition to the lipid treatm ent.
The initial 0-60 m M fructose treatments on HepG2 in serum-free low-glucose EMEM did 
not lead to any discernible increase in intracellular TAG. In addition, investigation of 0-100  
m M fructose treatments with a 60m M glucose co-treatment in each case in the same 
serum-free EMEM also did not result in an increase in intracellular TAG. This could mean 
that glucose has no direct influence upon the accumulation of intracellular TAG, if 
extraneous sources of fatty acids are absent. Glucose has already been shown, in HepG2, to 
be unable to influence apoBlOO VLDL-TAG export as glucose was found to be a very poor 
substrate for TAG synthesis in HepG2 (Jiang, et al. 1998). A requirement for extraneous 
fatty acids might be the true determinant for HepG2 increasing intracellular TAG, if a 
sufficient level of glucose is available.
It is of interest that in the methods sections of several papers that describe lipid-overload 
models in hepatoma cell culture (in the main HepG2 or HuH7, reviewed in (Chavez-Tapia, et 
al. 2011)), that the lipid treatments are carried out in serum-free media without any 
specification of the media glucose concentration. It may be the case that since high-glucose 
media is commonly used in many pharmacology and molecular-toxicology experiments 
(because in these models, the media glucose concentration is of no relevance), that 
nutritional models of NAFLD have inherited the use of high-glucose media without further
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examination of the influence of glucose upon lipid-treatment in HepGZ or HuH7 
hepatocytes.
Neither in the current study, nor in that by Collison and co-workers (Collison et al. 2009), is 
any account made of the utilisation of fructose, or glucose from the treatm ent media. It is 
not known whether the fructose delivered in our treatments ever enters our HepG2 cells 
(given the requirement for GLUT2). If it cannot enter our cells, but apparently can enter the 
HepG2 cells used by the Collison group, then that would explain our inability to induce lipid 
accumulation with fructose treatments, even with the 60 mM glucose co-treatments. 
However, as Collison did not perform any treatments in serum-free media (assuring an 
absence of lipid), we cannot know if the increase in intracellular TAG in the Collison model 
is due to conversion of fructose to lipid, or whether fructose just diverts NEFA from the 
media towards TAG synthesis. Radiolabelled fructose as used for example, by (Hirahatake, 
et al. 2011) would be useful in order to track the fate of fructose when used to treat HepG2 
hepatocytes.
In neither the current study, nor in that by Collison and co-workers, is any account made of 
the production and secretion of TAG associated with apoBlOO particles, or of secretion of 
fatty acids to the culture media by the HepG2 cells. Perhaps fructose (and possibly glucose) 
gets converted to TAG, but is exported from HepG2 cells without any appreciable 
accumulation of intracellular TAG due to the constitutive activity of apoBlOO VLDL export 
that has previously been documented in HepG2 cells (Pullinger, et al. 1989), and that is also 
inhibited by insulin (Cianflone, et al. 1992). This could be investigated further through 
pharmacological inhibition of mitochondrial triglyceride transfer protein (MTTP), which 
serves as the rate-limiting step in VLDL export from hepatocytes (Meex, et al. 2011).
2.4.2 Cell Viability
Fructose treatments (0-60 m M) did not affect cell viability in these studies. The decrease in 
cell viability (as inferred from LDH-release into culture media) from 4 8 h and until 96h after 
initial fructose treatm ent (0-60 mM) was exhibited by all samples. This suggests that under 
the conditions tested, increasing fructose treatm ent concentrations do not differentially 
affect LDH release from HepG2. However, as only two biological replicates were tested, 
more studies would need to be performed in order to demonstrate this result conclusively. 
PA treatments (0-200 piM) may have decreased cell viability over 24h. The decrease in cell 
viability from 6h and until 24h after initial palmitate treatm ent (0-200 piM) was greater and
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occurred more rapidly at higher PA-treatment concentrations (greater than 100 piM, with 
200 [iM, the highest treatm ent tested, exhibiting the largest and most rapid decrease). This 
suggests that under the conditions tested, increasing PA treatm ent concentrations 
differentially affect LDH release from HepG2. However, as only two biological replicates 
were tested, more studies would need to be performed in order to demonstrate this result 
robustly.
The method for measuring cell viability by LDH-release was improved in later cultures of 
primary hepatocytes. In the experiments on mouse primary hepatocytes (Chapter 3), which 
were done after the HepG2 fructose and PA treatm ent experiments discussed here, 
methodological improvements upon our approach for sampling culture media over the 
time course of the experiments were achieved as a result of the kind suggestion of one of 
our colleagues. Future measurement of LDH release to infer changes of cell viability must 
sample the culture media at the very outset of a treatm ent (i.e. T=0 h) in order for robust 
comparisons to be drawn.
LDH-release serves as a non-specific indication of disrupted cell membrane integrity. It may 
be the case that fructose does not affect HepG2 cell membranes to any greater degree as 
fructose concentration is increased, in contrast to the effects of increasing PA 
concentration. A caveat however, that applies to both of the experiments is that it would 
have been much more instructive to have data from culture media at time points 
equivalent to T=Oh to act as a baseline level. The methyl tétrazolium (MTT) assay measures 
the accumulation of the insoluble purple formazan product that results from the cleavage 
of the MTT tétrazolium ring by succinate dehydrogenase, or from its reduction by NADH or 
by NADPH within the cells (Fotakis & Timbrell, 2006). Comparisons of LDH assay for 
assessing cytotoxicity via membrane damage and the MTT assay for assessing cytotoxicity 
via altered mitochondrial metabolism have been made for various toxicological insults 
(Fotakis & Timbrell, 2006). It would be useful to compare the effectiveness of LDH and MTT 
assays for assessing both of the fructose and PA treatm ent models. It may be the case that 
both PA and fructose have cytotoxic effects upon HepG2 cells. However, it may also be the  
case only PA stimulates LDH-release due to membrane damage, while fructose does not 
cause harm of a kind that results in LDH-release. If this were the case, then a different 
means of assessing cytotoxicity might be more appropriate for use in assessing the  
cytotoxic effects of fructose.
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In other studies performed by Lee and co-workers (Lee, et al. 2009), fructose alone was 
only found to be toxic after 2h exposure in primary hepatocytes with an EC50 of 1.5M, 
which is a supraphysiological treatm ent dose. However, 12 m M fructose was able to induce 
50% cell death within 2 h of administration provided that the fructose-treated primary 
hepatocytes had already been subject to a non-toxic exposure to H2O2 that was 
continuously generated by reaction of glucose with glucose oxidase. This requirement for a 
background of oxidative stress was further investigated by measurement of hepatocyte 
ROS-generation, mitochondrial toxicity and cytotoxicity. Cytotoxicity was assessed in these 
studies by the percentage-uptake of trypan blue, rather than by LDH-release to culture 
media.
Additional investigation by Lee and co-workers concluded that in primary hepatocytes, 
cytotoxicity from fructose with H2O2 was likely due to oxidation of fructose to carbonyl 
radicals such as glyoxal, and that this oxidation was catalysed by ROS, transition metals and 
cytochrome P450 enzymes. For example, 15 mM fructose cytotoxicity activated by H2 O2 
was prevented by the separate inclusion of the vitamins thiamine and pyridoxal, which 
scavenge hydroxyl radicals, or dehydroascorbate (a superoxide scavenger) and also by the  
cofactor carnitine. Attenuation of hepatocyte ROS-generation by nontoxic tert- 
butylhydroperoxide (instead of H2O2 ) and 15 m M fructose co-treatment was achieved by 
use of a general cytochrome P450 (CYP450) inhibitor such as 1-aminobenzotriazole, or 
more specific CYP2E1 inhibitors such as phenylimidazole or chlorzoxazone. These vitamins 
and P450 inhibitors also maintained the hepatocyte mitochondrial membrane potential in 
the face of increased ROS generation and fructose. Further, the role of dicarbonyl and 
hydroxyl radicals in the mechanism of fructose-induced cytotoxicity was also suggested by 
the ability of dicarbonyl or hydroxyl radical scavengers such as aminoguanidine to 
attenuate fructose and H2O2 co-treated hepatocyte cytotoxicity, ROS-formation, and H2 O2 
generation while also maintaining mitochondrial respiration. Additionally, the H2 O2- 
acitvated fructose cytotoxicity in primary hepatocytes could also be increased by iron or 
copper, and rescued by iron-chelating agents, suggesting that these transition metals 
catalyse the formation of ROS and oxidation of fructose to dicarbonyl compounds, which 
have been implicated in NAFLD-pathophysiology (Lim et al, 2011).
Collison and co-workers (Collison, et al. 2009) assessed the effect of HFCS treatm ent on 
HepG2 oxidative stress and cell viability through imaging of HepG2 mitochondrial integrity 
by demonstrating depletion of MitoTracker Green staining and decreased co-localised
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immunofluorescent stain of cytochrome C in a dose-dependent manner. Release of 
cytochrome C was decreased from nuclear fractions of HepGZ cells, while concomitantly 
increased in cytosolic fractions in a dose-dependent fashion. Further, Collison and co­
workers also showed that in HepGZ increased production of reactive oxygen metabolites 
dose-dependently over untreated controls, and that the antioxidant epigallocatechin-3- 
gallate was able to ameliorate the production of reactive oxygen metabolites. No 
assessment was made of LDH-release to culture media.
2.4.3 Culture Requirements For Effective Lipid-Treatment of HepG2
Culture and treatm ent of HepGZ cells with 0-200 pM PA in either low-glucose EMEM or
low-glucose DMEM failed to elicit a consistent dose-response in terms of intracellular TAG 
content. This was the case irrespective of the use of a collagen substratum.
Increasing the dosing-range from 0-200 p M  PA up to 0-400 p M  PA did not reliably lead to  
any improvement in terms of observable dose-response to PA-overload while using low- 
glucose DMEM. The later experiments investigating whether the use of high-glucose (25 
mM rather than 5 m M) DMEM affected the HepGZ dose-response to lipid treatm ent (0-500 
p M  OA) appeared fruitful. This variable was chosen for investigation after the realisation 
that our other model demonstrated the effectiveness of 0-200 p M  PA treatments upon 
inducing lipid accumulation in Huh7 cells in high-glucose DMEM. A review of other 
hepatoma models of lipid accumulation revealed that published methods sections seldom 
specify the exact nature of the culture media chosen for the work (Gomez-Lechon, et al. 
2007, Srivastava, 2008, Ricchi, et al. 2009, Cui, et al. 2010, Lee, et al. 2010). The apparent 
requirement of the high-glucose condition may have been overlooked. It would be 
informative to characterise the exact nature of the apparent requirement for glucose that 
the HepGZ cell line has in order for lipid accumulation to occur effectively.
2.4.4 Glucose-Based Models of Lipid Accumulation in HepG2
Several studies, performed in HepGZ (Guo, et al. 2011, Do, et al. 2013, Hou, et al. 2008,
Shang, et al. 2008, Hwang, et al. 2013, Zang, et al. 2004), show lipid accumulation arising 
from increasing culture media glucose concentration from 5.5 m M to 25 or 30 m M . There is 
typically a 2-3-fold increase of intracellular TAG over 24h, if the HepGZ cells are cultured in 
low-glucose media without an FBS supplement overnight prior to high-glucose exposure. 
This period of culture in the absence of sera, may have the effect of removing lipids from  
the cells that would otherwise remain within the HepGZ cell intracellular TAG pool. These 
models of glucose-induced lipid accumulation have then been used to investigate effects of 
various compounds to attenuate such glucose-stimulated lipid accumulation.
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As an example, in HepG2, mitochondrial G PAT (mtGPAT) translocation from the 
endoplasmic reticulum to the outer mitochondrial membrane (O M M ) is stimulated by 
increasing DMEM glucose concentration from 5 m M to 25 mM (Guo, et al. 2011), and this 
glucose stimulated increase in O M M  mtGPAT translocation was attenuated by anthocyanin 
in a dose-dependent manner. The enzyme activity of OMM-associated mtGPAT was also 
found to be higher than that of ER-associated mtGPAT, and the HepG2 intracellular TAG 
pool was shown to be "significantly" greater under the high-glucose condition relative to 
that of the low-glucose media, in accordance with the greater activity of mtGPAT. This is 
confirmed by quantification of intracellular TAG, and Oil Red-0 staining of lipid droplets for 
HepG2 cells cultured at low and high-glucose (with 10%FBS in the DMEM -  a possible 
confounding source of NEFA as already alluded to).
Do and co-workers (Do, et al. 2013) demonstrated that the glucoside phillyrin could 
counteract glucose-induced lipid accumulation in HepG2 cells by inhibiting the SREBP-lc- 
mediated expression of FAS. This effect of phillyrin was dependent on the activation of 
AMPK, the activation of which was shown to be due to the phillyrin-stimulated 
phosphorylation of liver kinase B-1 (LKBl). In this model, the lipid accumulation induced by 
increasing culture media glucose concentration from 5.5 mM to 30 mM resulted in HepG2 
intracellular TAG/protein increasing from 30 pg/mg to approximately 100 pg/mg. Prior to 
increasing the media glucose to 30 m M, the cells were acclimated in serum-free low- 
glucose media for an unspecified period of time.
Another group showed that polyphenolic compounds including resveratrol were capable of 
inhibiting the stimulation of glucose-mediated lipid accumulation in HepG2 cells by 
bolstering the phosphorylation and thus activation of the histone deacetylase sirtuin 1 
(SIRTl) (Hou, et al. 2008). Culture of HepG2 cells in 5.5 m M  glucose-containing media and 
followed by 24h in 30 mM glucose-containing media lead to a two-fold rise in intracellular 
TAG (from approximately 40 pg/mg total protein to 80 pg/mg). Here the cell culture media 
contained 10% (v/v) FBS. Another study (Shang, et al. 2008), investigating the effect of 
AMPK-activation by resveratrol showed that resveratrol could attenuate the lipid 
accumulation caused by treating HepG2 cells that had been grown in 5.5 m M glucose 
DMEM with 10% (v/v) FBS with 25 mM glucose serum-free DMEM with 100 nM insulin. 
Prior to high-glucose and insulin treatm ent, the HepG2 cells were also cultured in serum- 
free 5.5 mM DMEM for a brief period. Treatment caused HepG2 intracellular TAG to 
increase from 50 pg/mg total protein to 140 pg/mg.
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Transition of HepGZ cells cultured in 5.5 mM glucose DMEM with 10 (v/v) FBS to 30 mM  
glucose -containing serum-free DMEM was shown (Hwang, et al. 2013) to stimulate lipid 
accumulation in HepG2 cells, and this increase of intracellular TAG could be attenuated by 
administration of saponin compounds. For this model of glucose-induced lipid 
accumulation, there was also a period of acclimation in serum-free 5.5 mM glucose DMEM  
immediately prior to treatm ent with serum-free 30 mM-glucose DMEM. HepG2 
intracellular TAG was increased from 45 pg/mg total protein to 130 pg/mg. The 
requirement for AMPK activation in order for metformin to ameliorate high-glucose 
induced lipid accumulation was demonstrated in HepG2 (Zang, et al. 2004). Again, this 
model utilised growth of cells in 5.5 mM glucose DMEM with 10% (v/v) FBS until 70% 
confluent, then an overnight period of acclimation in serum-free 5.5m M  glucose DMEM, 
followed by treatm ent in serum-free 30 mM glucose DMEM. HepG2 intracellular TAG was 
increased from 35 pg/mg total protein to 110 pg/mg.
Review of these glucose-based models of lipid accumulation suggests that the achievement 
of lipid accumulation among these models may depend on keeping the HepG2 cells in 
serum-free low-glucose media for an overnight period to allow dissipation of any lipid that 
was within the cells under low-glucose conditions while grown with an FBS supplement. 
The lipid accumulation that results when these models transition from low-glucose to high- 
glucose serum-free media, reflects that the cells have been allowed to rid themselves of 
accumulated lipid before glucose-treatment. The lipid accumulation recorded following 
high-glucose exposure is only relative to the very low levels observed in the cells having 
been acclimated in the low-glucose media, in the absence of serum. This could be relevant 
to the studies performed here, since HepG2 cells were grown with 10% FBS prior to PA 
treatm ent in serum-free EMEM or DMEM. Comparison of the difference in the extent of oil 
red-0 staining between HepG2 cells fixed before or control cells after treatm ent, is 
suggestive of intracellular lipid clearance over the 24 h treatm ent period in serum-free 
medium.
2.4.5 Summary
Fructose treatments and fructose-glucose co-treatments did not increase the intracellular 
TAG content of HepGZ human hepatocytes in these studies. Fructose treatments also did 
not alter HepGZ cell viability, as inferred from HepGZ cell LDH-release to media. Previous 
work (Lee, et al. 2009) has indicated that in the absence of simulated oxidative stress, 
primary hepatocytes treated with fructose were resilient to cytotoxicity (as indicated by 
trypan blue staining), with an EC50 of 1.5 M at 2h of fructose treatm ent. It can be
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concluded from these experiments that fructose treatm ent does not alter HepG2 lipid 
content, but that further assessments are necessary to fully determine the effect of 
fructose treatm ent on HepG2 cell viability.
Treatment with PA was able to modestly increase HepG2 intracellular TAG content, 
although results were inconsistent. PA treatm ent of HepG2 cells did appear to differentially 
decrease cell viability over 6-24h, although more studies would be needed in order to 
demonstrate this finding conclusively. OA treatm ent of HepG2 cells that were both cultured 
and treated in a high-glucose media provoked dose-dependent lipid accumulation as 
assessed by oil red-0 staining of intracellular lipid, although again more studies will be 
required in order to confirm this observation.
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3 Use of Primary Hepatocyte Cultures for Study of  
Intracellular Lipid Content
3.1 Introduction
Mouse primary hepatocytes were chosen as an alternative model for investigation of 
fructose treatm ent because the prior model that utilised HepG2 human hepatocytes had 
not shown any effect of fructose or fructose and glucose co-treatments upon hepatocyte 
lipid content. This was thought to be due to the reported over-expression of the enzyme 
hexokinase II in transformed human hepatocytes, which results in the over-expressed 
hexokinase II metabolising fructose to fructose-6 -phosphate, preventing metabolism of 
fructose to fructose-l-phosphate by fructokinase (Speicher, et al. 2010).
The goal of the following experiments was to successfully isolate mouse primary 
hepatocytes and investigate the effects of fructose treatments with respect to hepatocyte 
lipid content and cell viability.
3.2 Materials and Methods for Mouse Primary Hepatocyte Isolation
3.2.1 Collagen -Coating Culture Ware for Primary Hepatocyte Culture
Cultureware was collagen-coated for primary hepatocyte culture using the same method
detailed in Chapter 2.2.3.
3.2.2 Preparation for Liver Perfusion
Krebs-Henseleit Buffer (KHB) (Krebs & Henseleit, 1932) was produced with the following 
constituent final concentrations: NaCI 120.27 m M, KCI 4.81 m M, KH2 PO4  1.20 m M , MgS0 4  
1.20 m M, NaHCOs 25.26 m M, glucose 5.50 mM (Mischinger, Walsh et al. 1992), EGTA 0.53 
m M, Penicillin/Streptomycin 100 U/ml. The KHB was adjusted to pH 7.40 (+/-0.02).
C0 C/2  (150 mM): 1.03g of calcium chloride (dihydrate) in 50ml of ddH2 0 . Filtered through 
22 [im and stored at 4°C.
Collagenase IV (32 mg/ml): 675 mg Bacterial Collagenase IV (Roche, Welwyn Garden City, 
UK) dissolved in 21 mL of KHB (without glucose or EGTA, with Pen/Strep). Filtered through 
a 22 pm membrane and stored at -20°C in 7.0 mL aliquots.
Fatty Acid-Free Bovine Serum Albumin (FAF-BSA) (36 mg/mL) 1820 mg FAF-BSA (Sigma) 
dissolved in 50 mL KHB (without glucose or EGTA, with Pen/Strep). Filtered through 0.22 
pm membrane and stored at 4°C.
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No animals were sacrificed solely for the purposes of this project. Tissue was obtained from 
animals that were culled at the end of other projects within the University, according to 
Schedule 1 procedure (CO2 asphyxiation and cervical dislocation). Sterile KHB (200ml), with 
0.5 mM EGTA, and 1% (v/v) Pen/Strep, was warmed to 39°C in a waterbath, and pumped 
around the apparatus (peristaltic pump model 205U, Watson-Marlow), clearing air from  
the tubing and securely attached 30G needle.
3.2.3 Perfusion Method
From the recently sacrificed animal, the chest cavity was exposed and tissue was perfused 
via the superior vena cava. Calcium-free perfusate (60 ml) was pumped through to waste 
over a period of at least 15 minutes, clearing the liver of blood. Collagenase (7.0 ml of 32 
mg/ml solution) and 4.0 ml CaCb (150 m M) were added to 140 ml of perfusion mixture, 
giving final concentrations of 1.5 mg/ml collagenase, and 4 mM CaCl2, in a volume of 151 
ml. Perfusion was continued for a further 7 minutes until the liver was digested (extent of 
digestion gauged by blunt forceps indentation). The liver was then dissected and 
transferred to a sterile Petri dish in a laminar flow hood. A 50 ml portion of the collagenase- 
containing perfusate was used (in small batches) to tease out the cells from the liver using 
sterile tissue forceps. The batches of suspended cells were added to a 100 ml beaker and 
the remaining liver was discarded. The cell solution was then covered and incubated in the  
waterbath for a further 10 min at 37°C with gentle shaking (60 oscillations/min).
In the laminar flow hood, the 50 m l suspension was divided equally through a 70 pm sterile 
tissue culture filter into two sterile Universal tubes. These were centrifuged at 50g for 3 
min. The supernatant was discarded and the cell pellet gently resuspended with 25 m l of 
sterile BSA in KHB (36 mg/ml, without EGTA or glucose, with Pen/Strep). They were then 
centrifuged again at 50g for 3 minutes, the supernatant discarded, and cells resuspended in 
25ml ice-cold KHB (without EGTA and glucose; but with Pen/Strep). Next, cells were 
resuspended in 40 ml of low-glucose DMEM (with 10% (v/v) PBS, 2 mM L-glutamine, 0.1 
mM NEAA and 100 U/ml penicillin/streptomycin). The cell count and viability were 
determined by haemocytometer and trypan-blue staining.
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Sacrifice C57BL/6, dissect and perfuse liver. Expose chest cavity and perfuse liver via the superior vena cava
Pump Ca -free perfusate (60 ml) through to waste over a period 
of at least 15 minutes, clearing the liver of blood.
/Add collagenase (7.0 ml of 32 mg/ml solution) and 4.0 ml C a C I^  
/ (150 mM) were added to 140 ml of perfusion mixture, (final
I concentrations: 1.5 mg/ml collagenase, 4 mM CaCIa, In a volume 
of 151 ml). y
Continue perfusion for a further 7 minutes until the liver was 
digested. Then transfer dissected liver to a sterile Petri dish In a 
laminar flow hood.
Disrupt liver tissue to obtain crude cell 
suspension
In a 50 ml portion of collagenase-contalning perfusate, tease out 
the cells from the liver using sterile tissue forceps.
Suspend the cells In a 100 ml beaker. Discard the remaining liver.
Cover the cell solution and Incubate In the waterbath for a further \  
10 min at 37°C with gentle shaking (60 osclllatlons/mln). J
Ar\ the laminar flow hood, divide the 50 ml suspension equally and\ 
filter through a 70 pm sterile tissue culture and filter Into two sterile I
Universal tubes.
Isolate parenchymal cells from crude perfusate.
Centrifuge cells at 50g for 3 min. Discard supernatant and 
resuspend cell pellet with 25 mL of sterile BSA In KHB (36 mg/ml, 
without EGTA or glucose, with Pen/Strep).
i z
Centrifuge cells again at 50g for 3 minutes, discard supernatant, 
and resuspend cells In 25ml Ice-cold KHB (without EGTA and 
glucose: but with Pen/Strep).
i z
Resuspend cells In 40 ml of low-glucose DMEM (with 10% 
(v/v) PBS, 2 mM L-glutamlne, 0.1 mM NEAA and 100 U/ml 
. penlclllln/streptomycin).
Determine cell count and viability, seed primary 
hepatocytes onto cultureware.
Determine cell count and viability by haemocytometer 
and trypan-blue staining (minimum 90% of cells clear of 
trypan-blue).
Figure 3-1 -  Primary Hepatocyte Isolation Procedure.
3.2.4 Primary Hepatocyte Cell Culture
Cells were plated at 8.0 x lO'  ^ per cm^ and then following a 1 hour interval, the plating 
media and extraneous, unattached cells were gently aspirated away leaving the monolayer 
of primary hepatocytes attached to the collagen-coated culture vessel. Fresh supplemented
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DMEM culture medium was then added carefully to the culture vessels before returning 
them to be incubated at 37°C and 95% 02:5%C02. At 4h post-seeding, the low-glucose 
DMEM supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 0.1 mM NEAA and 100 U/ml 
penicillin/streptomycin was replaced with serum-free supplemented DMEM.
3.2.5 Fructose and Palmitate Treatments of Mouse Primary Hepatocytes
0-50 mM fructose treatments and 50 pM palmitate treatments were prepared as described
in Chapter 2.2.4 and 2.2.5 for use with mouse primary hepatocytes.
3.2.6 Assay of Mouse Primary Hepatocytes
Oil red-0 lipid staining, the triacylglycerol assay and the cell viability assay were performed 
with mouse primary hepatocyte cells in a similar manner to that with HepG2 cells as 
described in Chapter 2.2.6, 2.2.7 and 2.2.8.
3.2.7 Statistical Methods
One-way ANOVA and two-way ANOVA were performed using GraphPad PRISM 6.01 
(GraphPad software, Inc. USA).
3.2.8 Summary of Treatments
Table 3.1; Fructose Treatments of Mouse Primary Hepatocytes 
Treatment Culture Media Time Points Assays Performed Rationale
0-50 mM Fructose 25 mM Glucose 
DMEM
96 h TAG, LDH Test effect of fructose 
on primary 
hepatocytes
0-50 mM Fructose 
0-200 pM PA 
0-50 mM Fructose 
+ 50 pM PA
25 mM Glucose 
DMEM
24 h ORO Test effect of fructose 
or palmitate, or 
fructose with palmitate
0-20 mM Fructose 25 mM Glucose 
DMEM
4h, 20h ORO Observe lipid content 
before and after 
fructose Tx
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Table 3.2: Further Treatments of Mouse Primary Hepatocytes
Treatment Culture Media Time Points Assays Performed Rationale
+/- serum 5 or 25 mM 
Glucose DMEM
+serum: 2,4,8 h 
- serum: 4 ,8 ,24h
ORO Test if presence of 
serum influences lipid 
content
1 or 5 mM Glucose 1 or 5 mM 
Glucose DMEM
20h ORO Test if lower glucose 
concentrations 
influence lipid content
1 mM Glucose 
0.2 or 1.0 mM 
pyruvate;
5 mM Glucose 
1 mM pyruvate
1 or 5 mM 
Glucose DMEM
4 h, 20 h ORO Test if addition of 
alternative substrate 
influences lipid content
+/- 5 mM Glucose in 
Isolation Buffer
1 or 5 mM 
Glucose DMEM
4 h, 20 h ORO, TAG Test if removal of 
glucose from KHB 
influences lipid content
5 or 10 mM Ca^* in 
Isolation Buffer
1 or 5 mM 
Glucose DMEM
4 h, 20 h ORO, TAG Test if decrease of 
KHB Ca^* influences 
lipid content
Male vs. Female 
animal
1 or 5 mM 
Glucose DMEM
4 h, 20 h TAG Test if animal gender 
influences lipid content
2 Male vs. 1 Female 
animal
1,5 ,12.5 or 25 
mM Glucose 
DMEM
4 h, 24 h, 48 h, 
72 h, 96 h
ORO, TAG Test if animal gender 
influences lipid content
2 Male animals 1 or 5 mM 
Glucose DMEM
0 h, 24 h, 48 h, 
72 h, 96 h
ORO, TAG Test if glucose 
influences lipid content
6 6
3.3 Results
3.3.1 Effect of Fructose Treatment on Intracellular TAG in Mouse Primary 
Hepatocytes
The effects of 96h of fructose treatm ent on cells that had been cultured in DMEM for 24h 
prior to treatm ent were investigated. In initial experiments, the primary hepatocytes were 
cultured in standard "high-glucose" DMEM (25 mM glucose). This was to simulate the 
conditions of hyperglycaemia. Fructose treatments of 0-50 mM did not alter the 
intracellular TAG content of the primary hepatocytes (after analysis with one-way ANOVA), 
and high levels of intracellular TAG were observed in all instances following four separate 
experiments (Figure 3.1).
Ü
4000 ^
3000 -
2000 -
1000 -
 1-----
10 20 30
Fructose (mM)
~ r~
50
Figure 3-2 - Fructose Treatment of 
Mouse Primary Hepatocytes.
Mouse primary hepatocytes w ere  
treated with 0-50 m M  fructose in 
25 m M  glucose serum-free DMEM  
for 96h. TAG content was 
measured by enzymatic assay and 
normalized to total protein 
content. Data represent mean and 
SD of four independent cultures of 
primary hepatocytes. No significant 
differences w ere found by one-way  
ANOVA.
3.3.2 Effect of Fructose Treatment on Cell Viability of Mouse Primary 
Hepatocytes
LDH-release from mouse primary hepatocytes cultured under high-glucose conditions was 
not affected by additional fructose treatm ent (Figure 3.2). From the start of fructose 
treatm ent to the 96h final time point, cells for all treatments (0 mM, 5 m M, 10 m M, 20 
m M, 30 mM and 50 m M) exhibited similar decreases in cell viability (as inferred from LDH 
release to culture media). However, for all fructose treatments, a highly significant effect of 
time was observed (P<0.0001).
Samples from cells treated with high-glucose culture media with and without the 10% (v/v) 
FBS supplement was also sampled in order to permit a comparison to samples taken from  
fructose-treated cells (each without FBS). The presence of FBS in the cell culture media also 
had no obvious effect on mouse primary hepatocyte cell viability over the course of 96h of 
culture.
67
JD
CO
:>
■q>
O
100-1
8 0 -
6 0 -
4 0 -
2 0 -
0 6 12 18 24 48 72 96
OmM 
* '  5 mM 
- A -  10 mM 
- A -  20 mM 
- # -  30 mM 
— 50 mM 
—"—  + Se rum 
 -Serum
Hours after Fructose Treatment 
Figure 3-3 - Cell V iability o f Fructose Treated Mouse Primary Hepatocytes.
Mouse primary hepatocytes w ere treated with 0-50 m M  fructose in 25 m M  glucose serum-free  
DMEM for 96h. Treatm ent media LDH content was measured by enzymatic assay. Data represent 
mean and SD of five independent cultures of primary hepatocytes. No significant differences were  
found by two-w ay ANOVA.
3.3.3 Effect of Treatment of Primary Mouse Hepatocytes with Either or Both 
Fructose and Palmitate on Hepatocyte Lipid Content
Mouse primary hepatocytes were isolated and treated in serum-free high-glucose (25 m M)
DMEM for 24h. Using these cells (all from the same animal), three different sets of 
treatm ent conditions were tested. One group of primary hepatocytes was treated with 0- 
50 mM fructose, as in the previous experiments. Another was treated with 0-200 |iM  PA, 
and the third group of cells were treated with 0-50 mM fructose with the addition of a 50 
|iM  co-treatment of PA with each fructose treatm ent. All groups of primary hepatocytes 
exhibited extensive lipid content, as shown by Oil Red-0 staining of the cells following 24h 
of treatm ent (Figure3.3).
The fructose-only group displayed large lipid droplets (macrovesicles), which were 
apparent at each treatm ent concentration 0-50 mM. Unusual cell morphology could be 
observed if the fructose treatm ent concentration was greater than 10 mM (i.e. examples at 
20, 30 or 50 mM). Cells appeared smaller and more globular, suggestive of a partial 
detachment of the cells from the collagen substratum at the higher fructose treatm ent 
doses.
6 8
The PA-only group also displayed large, macrovesicular lipid droplets under each treatm ent 
condition, including the 0 pM PA control. The extent and size of lipid droplets observed in 
the PA-only-treated cells appeared slightly greater upon visual inspection in the cells that 
received 50-200 pM PA than the untreated cells, although this observation was not 
confirmed quantitatively by performance of the TAG assay. The 200 pM PA dose similarly 
altered the morphology of the hepatocytes, in comparison to lower PA doses, although this 
again is based only on visual inspection.
The final group of primary hepatocytes was treated with 50 pM PA and the 0-50 m M range 
of fructose treatments. Again, an extensive display of Oil Red-0 stained lipid droplets was 
visible under each condition, and a distinct alteration of cell morphology visually observed 
at fructose treatm ent concentrations greater than 10 m M, with cells appearing more 
globular and less attached to the substratum at the higher fructose doses than at the lower 
doses.
Overall, high lipid presence was observed irrespective of fructose or PA treatm ent 
concentration. PA may have had an additive effect upon lipid content in these cells, 
however, given the high levels of lipid observed in every case, a dose-dependent 
relationship between PA treatm ent concentration and lipid content is difficult to discern 
with confidence. As the high-glucose (25 mM DMEM) culture condition was used for each 
group of hepatocytes, it could be the case that the high levels of lipid were due to the  
glucose content of the culture media, masking the potential effects of fructose and PA 
treatments upon primary hepatocyte intracellular lipid content.
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Figure 3-4 - Treatm ent of Primary Mouse Hepatocytes w ith  Either or Both Fructose and Palm itate  
Did Not Affect Hepatocyte Lipid Content.
Oil Red-0 staining of mouse primary hepatocytes cultured in serum-free DM EM  with 25 m M  glucose 
for 24h, and treated with 0-50 mM fructose (left column), 0-200 pM palmitate (m iddle column), or 
0-50 m M  fructose with an additional 50 pM palmitate (right column). Images were taken using the  
Nikon 1000 fluorescent microscope with NIS-Elements 3.0 Software at 200X magnification. Cells 
w ere counterstained with haematoxylin.
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3.3.4 Effect of Fructose Treatment on Primary Mouse Hepatocyte Lipid Content
Additional studies were performed to investigate whether the primary hepatocytes
cultured at 25 mM glucose had visible lipid droplets prior to treatm ent with 0-20 mM  
fructose for 20h. Figure 3.4 shows that primary hepatocytes display apparently similar 
levels of lipid presence following only the 4h "sit-down" period (cultured in 25 mM glucose 
DMEM with a 10% FBS supplement) as they did after being washed with warmed PBS twice 
and then cultured for a further 20h with 0, 5 ,1 0  or 20 m M fructose treatments.
Similar to what was found in the previous experiment (Figure 3.3), here fructose 
treatments of more than 10 mM appeared to alter the cell morphology, suggestive of 
detachment of the cells form the substratum.
Figure 3-5 - Presence of Lipid 
Observed W ith in  4h of 
Primary Hepatocyte  
Isolation.
Oil Red-0 staining of mouse 
primary hepatocytes 
cultured in serum-free 
DMEM with 25 m M  glucose 
for 4h (A), and then treated  
for 20 h with 0 m M  fructose 
(B), 5 m M  fructose (C), 10 
m M  fructose (D) or 20 m M  
fructose (E). Images w ere  
taken using the Nikon 1000 
fluorescent microscope with  
NIS-Elements 3.0 Software at 
200X magnification. Cells 
w ere counterstained with  
haematoxylin.
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3.3.5 Histology of Mouse Liver Lobe Sections
To assess whether the liver tissue from the mice being used for isolation of primary 
hepatocytes was steatotic or not, 10 pm sections were taken from each of three separate 
lobes of the liver of an untreated animal. Expert histological examination (courtesy of Dr J 
Howarth) concluded that there was no evidence of steatosis from these liver sections 
(Figure 3.5). The white spaces that can be observed in the sections micrographed at 400X 
were deemed to be glycogen granules.
400X
a #  a a m
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Figure 3-6 - Haematoxylin and Eosin Staining of Flash-Frozen Mouse Liver Lobe Sections.
10 pm sections were taken from each of three separate lobes. Representative Images w ere taken 
using the Leica DMLB light microscope with the Le lea QWIn Software at IGOX (A, C and E) and 400X  
(B, D, and F) magnification and were verified by expert assessment (courtesy of Dr J Howarth).
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3.3.6 Comparison of Oil Red-0 Stain of Intracellular TAG Content in Low- 
Glucose or High-Glucose Media, With and Without FBS
Since the liver tissue prior to hepatocyte isolation was not steatotic, it appeared that lipid
presence was occurring at some stage during isolation of the cells and prior to either form  
of treatm ent (i.e. with fructose or palmitate). Based on this, the conditions of high glucose 
and also the presence of FBS in the media during the isolation 'sit-down' period were 
investigated to see whether either one contributes to the lipid presence observed. Primary 
hepatocytes were thus isolated and then cultured in DMEM with 10% (v/v) FBS at both 5 
mM and 25 mM glucose. Oil Red-0 stained lipid droplets could be observed from cells 
sampled at 2h, 4h and 8h post-seeding (Figure 3.6). Since lipid droplets were observed 
under both the low and high glucose conditions (5 mM and 25 mM) in the presence of FBS, 
the experiment was repeated in serum-free DMEM. Despite eliminating FBS from both the 
low and high glucose cultures, again lipid presence could be observed in cells sampled at 
4h, 8h and 24h post-seeding (Figure 3.7). Taking a cue from a 2011 paper (Osawa et al, 
2011), the subsequent experiments investigated whether glucose concentrations lower 
than 5 mM were necessary to produce primary hepatocytes cultures that had acceptable 
intracellular lipid content. However, even when cultured in serum-free DMEM containing 1 
mM glucose, mouse primary hepatocytes still exhibited similar lipid presence as cells 
cultured at 5 mM glucose (Figure 3.8).
5 m M
25 m M
»
Figure 3-7 - Mouse Primary Hepatocytes Cultured in Either Low-Glucose or High-Glucose- 
Containing M edia Display Presence of Lipid Soon A fter Isolation.
Oil Red-0 staining of mouse primary hepatocytes cultured in DM EM  with 10% FBS (v/v) and 5 mM  
glucose for 2h (A), 4h (C), or 8h (E). Cells w ere also cultured with 25 m M  glucose with 10% (v/v) FBS 
for 2h (8), 4h (D), or 8h (F). Images were taken using the Leica DMLB light microscope w ith the Leica 
QWin Software at 400X magnification. Cells w ere counterstained with haematoxylin.
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Figure 3-8 - Mouse Primary Hepatocytes Cultured in Either Low-Glucose or High-Giucose- 
Containing Serum-Free M edia Also Display Presence of Lipid Soon A fter Isolation.
Oil Red-0 staining of mouse primary hepatocytes cultured in serum-free DMEM with 5 m M  glucose 
for 4h (A), 8h (C), or 24h (E). Cells were also cultured in serum-free DMEM with 25 m M  glucose 4h 
(B), 8h (D), or 24h (F). Images were taken using the Leica DMLB light microscope with the Leica 
QWin Software at 400X magnification. Cells w ere counterstained with haematoxylin.
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Figure 3-9 - Mouse Primary Hepatocytes Cultured in Serum-Free Very Low-Glucose Serum-Free 
M edia Also Display Lipid Presence A fter Isolation.
Oil Red-0 staining of mouse primary hepatocytes cultured for 20h in serum-free DM EM  with 1 m M  
glucose (A), or 5 m M  glucose (8). Images w ere taken using the Leica DMLB light microscope with  
the Leica QWin Software at 400X magnification. Cells were counterstained with haematoxylin.
Provision of an easily utilised carbon source for energy such as pyruvate was also 
considered. Culture of primary hepatocytes with Im M  glucose DMEM containing 0.2 mM  
pyruvate, or 5 mM glucose DMEM containing 1.0 mM pyruvate still resulted in high levels 
of lipid after Oil Red-0 staining (Figure3.9).
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Figure 3-10 - Pyruvate Availability Did Not A lter Primary Hepatocyte Lipid Content.
Oil Red-0 staining of mouse primary hepatocytes cultured in serum-free DMEM with Im M  glucose 
and 0.2 mM pyruvate for 4h (A), Im M  glucose and 0.2 m M  pyruvate for 20h (B), Im M  glucose and 1 
mM pyruvate for 4h (C), Im M  glucose and 1 mM pyruvate for 20h (D), 5m M  glucose and 1 m M  
pyruvate for 4h (E), 5m M  glucose and 1 m M  pyruvate for 20h (F). Images were taken using the Leica 
DMLB light microscope with the Leica QWin Software at 400X magnification. Cells were  
counterstained with haematoxylin.
3.3.7 Glucose Concentration of Isolation Buffer Did Not Alter Lipid Presence in 
Primary Mouse Hepatocytes
Following isolation using KHB that had the standard 5.5 mM glucose concentration, and
after culture in DMEM at either 1 mM or 5 mM glucose, cells displayed very large lipid 
droplets at both the 4h and 20h time points (F igure 3 .1 0 ). The next experiment 
investigated whether removal of KHB glucose (i.e. from 5.5 mM down to 0 m M ) for the
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isolation could alter the extent of intracellular TAG. Following isolation using KHB that had 
0 mM glucose, and after culture in DMEM at either 1 mM or 5 mM glucose, cells still 
displayed very large lipid droplets for both the 4h and 20h time points (Fig.3.11).
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Figure 3-11 - Effect of Isolation Buffer W ith  Glucose on Lipid Presence in Mouse Primary 
Hepatocytes.
Oil Red-0 staining of mouse primary hepatocytes cultured in serum-free DMEM with 1 m M  glucose 
for 4h (A), 5 mM glucose for 4h (B), 1 m M  glucose for 20h (C), 5 m M  glucose for 20h (D). Cells were  
isolated using KHB that had 5 mM glucose. Images were taken using the Leica DMLB light 
microscope with the Leica OWin Software at 400X magnification. Cells w ere counterstained with  
haematoxylin. Intracellular TAG for cells isolated using KHB that had 5 mM glucose (E). TAG content 
was measured by enzymatic assay and normalized to total protein content.
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Figure 3-12 -  Effect o f Glucose-Free Isolation Buffer on Lipid Presence in M ouse Primary 
Hepatocytes.
Oil Red-O staining of mouse primary hepatocytes cultured in serum-free DMEM with 1 m M  glucose 
for 4h (A), 5 mM glucose for 4h (B), 1 m M  glucose for 20h (C), 5 m M  glucose for 20h (D). Cells w ere  
isolated using KHB that had 0 m M  glucose. Images were taken using the Leica DMLB light 
microscope with the Leica OWin Software at 400X magnification. Cells w ere counterstained with  
haematoxylin. Intracellular TAG for cells isolated using KHB that had 0 m M  glucose (E). TAG content 
was measured by enzymatic assay and normalized to total protein content.
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3.3.8 Effect of Reducing the Isolation Buffer Ca2+ Concentration on Lipid 
Presence
The two-step collagenase perfusion method (Seglen 1976) utilises calcium-free isolation 
buffer for the initial step in order to induce the irreversible cell separation of hepatocytes 
before calcium is added to the buffer to act as a cofactor for the collagenase digestion for 
the second isolation step. The second-step working concentration of Ca^  ^up until this point 
had been 10 m M, which could potentially alter signalling mechanisms that govern 
hepatocyte lipid metabolism (Williamson, et al. 1987, Somogyi, et al. 1992, Aromataris, et 
al. 2006). Reducing the isolation KHB Ca^ "" concentration from 10 mM to 5 mM however, 
did not alter the extent of lipid presence revealed by Oil Red-0 stain. KHB Ca^  ^
concentration was kept at 5 mM for future isolations.
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Figure 3-13 - Decreasing Isolation Buffer Calcium Concentration Did Not A lter Lipid Presence in 
Mouse Primary Hepatocytes.
Oil Red-0 staining of mouse primary hepatocytes cultured in serum-free DMEM with 1 m M  glucose 
for 4h (A), 5 m M  glucose for 4h (B), 1 mM glucose for 20h (C), 5 m M  glucose for 20h (D). Cells w ere  
isolated using KHB that had 5 m M  glucose and 5m M  Ca "^'. Images were taken using the Nikon 1000  
light microscope with the NIS-Elements F3.0 Software at 200X magnification.
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3.3.9 Lipid Presence Observed In Mouse Primary Hepatocytes Isolated from 
Male and Female Animals
Up until this point, primary hepatocytes had been obtained from female C57BL6 mice as
only these animals were available, the next experiment utilised a male C57BL6 (Figure 
3.13). It was hypothesised that animal gender could influence the extent of lipid present 
within cultured primary hepatocytes.
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Figure 3-14 - Intracellular Triacylglycerol Content of Mouse Primary Hepatocytes From Female and 
M ale Animals.
Mouse primary hepatocytes from a 35 week old female animal (A), and a 12 week old male animal 
(B) were cultured with media containing 1 m M  or 5 m M  glucose. TAG content was measured by 
enzymatic assay and normalized to total protein content. Data represent one isolation in each case.
The intracellular TAG from hepatocytes from a 12-week old male C57BL6 was much lower 
in comparison to the intracellular TAG from cells isolated from a 35-week old female. It 
then followed to investigate whether the extent of intracellular lipid within isolated mouse 
primary hepatocytes was the result of animal age at the time of isolation, or the animal 
gender. Further mouse primary hepatocytes isolated from 6-week old male C57BL6 and 7- 
week old male C57BL6 and a 26-week old female had high levels of intracellular TAG at all 
time points throughout separate 96h cultures, at glucose concentrations ranging from 1 
mM to 25 mM (Figure 3.14 and Figure 3.15). This range of glucose concentrations was 
tested as it would simulate the full range of glucose concentrations that hepatocytes could 
conceivably be exposed to physiologically. A 4h -  96h time course for the experiments was 
selected as it was hypothesised that primary hepatocyte lipid content could change over a 
sufficient period. A further experiment utilising recently-weaned 6 and 7 week old male 
animals in which hepatocytes were harvested immediately after the 4-hour "sit-down" 
period of cell attachment (here termed "Oh") showed high levels of intracellular TAG at this 
very early point of the primary culture (Figure 3.16 and Figure 3.17).
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Figure 3-15 - High Levels of Lipid Present In Mouse Primary Hepatocytes Isolated From Male Animals.
Representative images of Oil Red-0 stained mouse primary hepatocytes from a 6-w eek old male 
animal cultured in serum-free media with 1 m M , 5 m M , 12.5 m M  or 25 m M  glucose (Top). Images 
w ere taken using the Nikon 1000 light microscope with the NIS-Elements F3.0 Software at 200X 
magnification. Cells were counterstained with haematoxylin. Intracellular TAG levels of mouse 
primary hepatocytes from both 6-week old (A), and 7-week old (B) male animals, cultured with 1 
m M  or 25 m M  glucose in serum-free DM EM . TAG content was measured by enzymatic assay and 
normalized to total protein content. Data represent independent experiments.
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Figure 3-16 - High Levels of Lipid Present In Mouse Primary Hepatocytes Isolated From a Female Animal.
Representative images of Oil Red-0 stained mouse primary hepatocytes from a 26 week old fem ale  
animal cultured in serum-free media with 1 m M , 5 m M , 12.5 m M  or 25 m M  glucose (Top). Images 
w ere taken using the Nikon 1000 light microscope with the NIS-Elements F3.0 Software at 200X 
magnification. Cells were counterstained with haematoxylin. Intracellular TAG levels of mouse 
primary hepatocytes from a 26-week old fem ale animal, cultured with 1 m M  or 25 m M  glucose in 
serum-free DMEM (Bottom). TAG content was measured by enzymatic assay and normalized to total 
protein content. Data represent one experiment.
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Figure 3-17 - High Levels of 
Intracellular Triacylglycerol 
Present in Mouse Primary 
Hepatocytes Soon A fter 
Isolation.
Intracellular TAG content of 
mouse primary hepatocytes 
from 6 and 7-week male 
animals cultured with media 
containing Im M  or 5 mM  
glucose. TAG content was 
measured by enzymatic assay 
and normalised to total protein 
content. Data represent mean 
and variation of two  
independent experiments.
Figure 3-18 - High Levels of 
Intracellular Lipid Present in 
M ouse Primary Hepatocytes 
Soon A fter Isolation.
Representative images of Oil 
Red-0 stained mouse primary 
hepatocytes from a 6 week  
old male animal cultured in 
serum-free media with 1 m M , 
or 5 m M  glucose. Images 
w ere taken using the Nikon 
1000 light microscope with 
the NIS-Elements F3.0 
Software at 200X 
magnification. Cells w ere  
counterstained with 
haematoxylin.
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3.4 Discussion
3.4.1 Summary of Results
This chapter details a series of experiments performed on isolated mouse primary 
hepatocytes with the aim of investigating the effects of fructose on hepatocyte lipid 
content. Primary hepatocytes were chosen as an alternative model system because it had 
been found that prior fructose and glucose treatments on HepG2 human hepatocytes 
yielded no differences in lipid content in comparison to untreated controls, and that PA 
treatments of HepG2 human hepatocytes yielded only a modest (though statistically 
significant) rise in hepatocyte lipid content. In contrast to these findings, the mouse 
primary hepatocytes displayed high intracellular lipid content that did not differ between 
untreated control cultures and fructose-treated cultures. Cell viability of mouse primary 
hepatocytes decreased over the course of 96h of culture, and no statistically significant 
differences between primary hepatocytes receiving different fructose-treatments were 
observed.
The mouse primary hepatocytes had excessive intracellular TAG, despite manipulation of a 
several variables, including the isolation buffer glucose concentration (5 mM or 0 m M  
glucose); the isolation buffer Ca^  ^ concentration at the digestion step (10 m M  or 5 mM); 
the culture media FBS presence after the 4 hour 'sit-down' period (10% (v/v) or serum- 
free); and the culture media glucose concentration (testing a range from 1 m M  to 25 m M  
glucose). Once male animals became available, the lipid content of primary hepatocytes 
from male and female animals were compared, and the lipid content of primary 
hepatocytes from younger animals was compared with that of hepatocytes from older 
animals. As age-matched animals of both genders were not available, it is difficult to draw  
firm conclusions about the effect of animal age and gender on the lipid content of the 
cultured mouse primary hepatocytes.
Expert assessment of liver lobe sections that had not undergone the isolation procedure 
nor had been subject to any form of culture was that the naïve liver tissue had no evidence 
of lipid accumulation. Thus it appeared some variable was either making the cells gain 
intracellular lipid or else fail to lose it during or after the process of hepatocyte isolation.
3.4.2 Hepatocyte Cytosolic Triacylglycerol Stores Are the Main Source of Fatty 
Acids for VLDL-Triacylglycerol for Export from the Hepatocyte
A detailed analysis performed by Gibbons and Wiggins (Gibbons & Wiggins 1995) provides
considerable insight into the supply of fatty acids to primary hepatocytes and the transfer
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of fatty acids from the cytoplasm to the ER for incorporation into VLDL-TAG for export from 
the hepatocyte. The hepatocyte cytosolic pool of TAG is the major source of the fatty acids 
used in the production of VLDL particles that are the vehicle for export of TAG out of the 
hepatocyte. Very little (17-20%: Gibbons & Burnham, 1991) TAG that is exported as VLDL- 
TAG is obtained from other sources of fatty acids. The TAG from the cytosolic pool must be 
broken-down (lipolysis) and then the fatty acids shuttled to the ER for incorporation into 
VLDL and re-esterification into VLDL-TAG. Hepatocytes that have been depleted of 
intracellular TAG by overnight culture in the absence of any extracellular fatty acids 
demonstrate the effect of low-intracellular TAG concentration upon the rate of VLDL-TAG 
secretion. Following cytosolic-TAG depletion, if hepatocytes are cultured in medium that is 
replete with oleate, then the TAG-depleted cells secrete less VLDL-TAG than those that 
have not been subject to prior culture in oleate-free medium. The VLDL-TAG secretion rate 
ciosely matches the hepatocyte intracellular TAG concentration, and the transfer of fatty  
acids from the intracellular TAG pool for incorporation into VLDL-TAG for export is 
controlled by the rate of lipolysis of intracellular-TAG followed by re-esterification of the  
fatty acids released to form TAG within VLDL ready for secretion. The proportion of fatty  
acids derived from the cytosolic TAG pool that are incorporated into VLDL-TAG was 
measured by culturing hepatocytes with ^H-oleate and ^^C-glycerol, and comparison of the  
specific radioactivity of VLDL-TAG to that of the prior intracellular TAG, indicated no 
change, which would suggest that there was little contribution of newly-synthesised fatty  
acids. However, the specific radioactivity of VLDL-TAG was 70% lower than the earlier 
intracellular TAG content, which would indicate that some 70% of what was previously 
intracellular TAG had been lipolysed, released from the intracellular stores, and then re- 
esterified back in TAG for incorporation into VLDL-TAG. Addition of insulin to the culture 
media had the effect of suppressing the secretion of VLDL-TAG into the media by 60-70%, 
but insulin did not affect the proportion of the secreted amount that was sourced from  
lipolysis from intracellular TAG (Gibbons & Wiggins 1995).
Since the hepatocytes examined in the current studies were also cultured in the absence of 
extracellular sources of fatty acids, but had high levels of intracellular lipid then this 
situation would suggest that the lipid within the cytoplasm was not transferred to the ER 
for incorporation into VLDL-TAG. Sampling of culture media in order to measure both the  
export of VLDL-TAG and the lipid content of any exported VLDL-TAG would be useful to  
provide further information.
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3.4.3 Dexamethasone Decreases Primary Hepatocyte Intracellular Lipid 
Content
The current primary hepatocyte culture system has not yet been used to investigate the 
effects of hormones upon the isolated cells. It could be possible that, given that most 
primary culture methods report use of the synthetic glucocorticoid dexamethasone and do 
not report excessive intracellular TAG, then the problem of excessive lipid content is due to 
a lack of stimulation from glucocorticoids.
For example, Mangiapane and Brindley (1986) incubated primary hepatocytes for 42h with 
1 pM dexamethasone which lead to intracellular TAG content to be 58% of that in control 
hepatocytes similarly cultured but in the absence of dexamethasone. This reduction in cell 
lipid content was concomitant to a 120% rise in the culture medium lipid content. Several­
fold increases in apoE, apoBL and apoBH ("light" and "heavy" isoforms) VLDL-lipoprotein 
secretion were induced by culture with 100 nM dexamethasone. Addition of 2 nM insulin 
enhanced the effects of 100 nM dexamethasone on apoBL and apoBH (Martin-Sanz, et al. 
1990). In contrast to these results, culture of primary hepatocytes with 2 nM insulin alone 
inhibited the secretion of all three lipoproteins, and if primary hepatocytes were cultured 
with 50 nM insulin with 100 nM dexamethasone the stimulatory effects of dexamethasone 
on lipoprotein secretion were reversed (Martin-Sanz, et al. 1990).
In another study, addition of insulin to primary hepatocyte culture with dexamethasone 
also present from the start of culture caused VLDL-TAG output to fall on the first day 
(Duerden, et al. 1989). Addition of insulin to the supplemented medium, followed by the 
removal of insulin either on the following day of culture, or on the day after that, resulted 
in a rise of VLDL-TAG output from the hepatocytes. This could be interpreted that provided 
dexamethasone is present, although the initial addition of insulin suppresses hepatocyte 
VLDL-TAG export, there is also a stimulatory effect of insulin upon the formation of 
intracellular TAG, such that subsequent removal of this insulin leads to a greater release of 
VLDL-TAG due to the enhanced intracellular TAG content.
Other work by Bartlett and Gibbons (1988) has suggested that there may be a "biphasic" 
effect of insulin and dexamethasone co-administration upon TAG-synthesis and VLDL-TAG 
export from primary hepatocytes. The age and duration (in terms of days) of a culture and 
the hormonal treatm ent administered to it in part determined the effects of the treatm ent 
upon the secretion of VLDL cholesterol and VLDL-TAG. In untreated (no dexamethasone, no 
insulin) primary hepatocyte culture, over the course of several days the rates of excretion 
of TAG and cholesterol declined (Bartlett & Gibbons 1988). Addition of dexamethasone
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alone stimulated VLDL secretion by increasing amounts as the culture aged. Co-treatment 
of hepatocytes with lipogenic precursors (lactate and pyruvate) in addition to 
dexamethasone further stimulated the secretion of VLDL-TAG and cholesterol. This co­
stimulatory effect was more apparent in younger rather than older cultures (Bartlett & 
Gibbons 1988).
3.4.4 Dexamethasone is Necessary for Maintaining the Rate of Export ofVLDL- 
Triacylglycerol from Primary Hepatocytes
Duerden and co-workers (Duerden, et al. 1989) also found that the culture of hepatocytes
in a "basal" medium that did not have any dexamethasone led to a fall in the rate of VLDL- 
TAG secretion over 3 days of culture. This decrease in VLDL-TAG secretion rate occurred in 
spite of a rise in the hepatocyte intracellular TAG content. This implies that culturing 
hepatocytes in the absence of dexamethasone decreases the export of TAG from within the 
hepatocyte via VLDL-TAG secretion. Hepatocytes cultured in a "supplemented" medium 
(i.e. in the presence of dexamethasone, with additional oleate, lactate and pyruvate) did 
not vary their rate of output of VLDL-TAG over three days of culture, provided insulin was 
absent (Duerden, et al. 1989).
Three-day culture of hepatocytes with the basal medium (no dexamethasone, no oleate, 
lactate or pyruvate) without insulin lead to a lower intracellular TAG content on each of the 
three days of culture when compared to use of supplemented medium. Use of the 
supplemented media (with dexamethasone and 0.75 m M oleate, 10 m M lactate and 1 mM  
pyruvate) only resulted in a slight rise in TAG content however; this could be interpreted as 
being due to the inclusion of oleate, lactate and pyruvate within the mixture, acting as a 
source of additional carbon for the formation of TAG. The slight rise in TAG content is much 
less than that observed from the use of the basal medium with additional insulin (i.e. 
without dexamethasone, but also without additional carbon sources for intracellular TAG 
synthesis) (Duerden, et al. 1989). The absence of a glucocorticoid such as dexamethasone 
from the current primary hepatocyte culture studies presented here could explain the high 
lipid content observed in the primary hepatocytes so cultured.
3.4.5 Summary
In this chapter, a series of experiments were performed on isolated mouse primary 
hepatocytes with the goal of establishing a model of fructose-induced accumulation of TAG 
in the isolated liver cells. A variety of experiments were performed to resolve a technical 
issue, since the cultured hepatocytes consistently had a high degree of intraceilular lipid 
soon after isolation (as observed qualitatively by oil red-0 staining and quantitatively by
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assay of sample intracellular TAG content). Different parameters were considered for 
testing, and unfortunately, the work on primary hepatocytes described in this chapter did 
not find that any of the variables considered altered the high levels of intracellular lipid 
within hepatocytes. These cultures were performed in the absence of dexamethasone and 
insulin. Future work with mouse primary hepatocytes could test the roles of 
dexamethasone and insulin upon the intracellular TAG content of primary hepatocytes over 
the course of culture.
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4 General Discussion
4.1 Summary of Results
In the studies presented here, treatm ent of HepG2 human hepatocytes with fructose and 
fructose-glucose co-treatments did not result in accumulation of intracellular TAG. PA and 
OA treatments were also performed, in order to confirm whether these HepG2 cells could 
accumulate TAG by means of exposure to exogenous fatty acids. The conclusions of these 
separate studies were that the effect of PA treatm ent was inconsistent, and that OA 
treatm ent of these HepG2 cells was more effective in a higher glucose media. Fructose 
treatments of HepG2 also did not affect cell viability over 48h-96h after fructose treatm ent. 
Although fructose treatments did not alter HepG2 intracellular TAG content, as no account 
was made of fructose utilisation from culture media or of fructose metabolism within the  
HepG2 cells, it cannot be concluded that fructose treatments of these HepG2 cells do not 
alter de novo lipogenesis within the cells.
4.2 Metabolic Fate of Glucose and Fructose in Hepatoma Cell Lines
The data presented in these studies are in contrast to other studies in HepG2 in which lipid
accumulation was observed following treatm ent with fructose and glucose monomers from  
MFCS (Collison et al, 2010). Prior work by other researchers found that HepG2 human 
hepatocytes were unable to utilise glucose as a substrate for TAG synthesis (Jiang, et al. 
1998). However, another study, also utilising HepG2 as a model system showed by mass 
isotopomer distribution analysis that glucose constituted some 80% of the C in newly 
synthesised PA (Lee, et al. 1995), indicating that at least in those HepG2, de novo 
lipogenesis was active. Further, HepG2 cells treated with 5 mM fructose in addition to 
standard 5.5 mM glucose media were shown to metabolise fructose to fructose-1- 
phosphate, but no evidence was found of increased expression of lipogenic genes 
(Hirahatake, et al. 2011). Phenotypic drift could explain the inconsistent findings between 
different studies, as widely used cell lines such as HepG2 may diverge over time in terms of 
expressed features such as the capacity for de novo lipogenesis (Pan, et al. 2009).
Another consideration with respect to the capacity for lipid accumulation in HepG2 is the  
role that mtGPAT has in initiating the synthesis of TAG from glycerol and acyl groups. As 
detailed previously (Chapter 2) Guo and co-workers (Guo, et al. 2011) showed that mtGPAT 
localisation and action is dependent on the glucose concentration of the culture media, 
resulting in modest increases in HepG2 TAG content as media glucose was increased from 5
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m M to 25 m M. This implies that if media glucose concentration is low, then fatty acids will 
not be as readily incorporated into TAG as when glucose concentration is higher, due to the 
dependence on mtPAT for the addition of the first acyl group to glycerophosphate. This 
finding has implications for the design of cell culture models to test the effect of lipid 
treatments on TAG content in HepG2 cells.
4.3 Increased Hexokinase II Expression and the Warburg Effect
Warburg (Warburg, 1956) first described the state of aerobic glycolysis observed in rapidly
dividing tum our cells, having observed that cancer cells had an increased glucose-uptake 
and capacity for glycolysis and production of lactate. This enhanced aerobic glycolysis is 
without an accompanying level of aerobic respiration, and despite ample supply of oxygen, 
mitochondrial function appeared diminished. Subsequent investigation has shown that 
many cancer cell types, including HepG2, over-express HK-II, and HK-II is associated with 
mitochondria by binding to mitochondrial voltage-dependent anion channels (VDACs) 
(Nakashima, et al. 1986). This association with mitochondrial VDACs permits the HK-II 
enzymes immediate access to ATP that is exiting the mitochondria via the VDAC. HK-II is not 
subject to product-inhibition by its product glucose-6-phosphate (Bustamante, 1980). The 
consequences of this increased expression and activity of HK-II in cancer cell lines such as 
HepG2 are that giucose is preferentially metabolised by glycolysis, that oxidative 
phosphorylation is curtaiied, and that fructose metabolism is re-routed via HK-II, resulting 
in fructose being phosphorylated to fructose-6-phosphate rather than fructose -1- 
phosphate such that fructose is shunted into glycolytic metabolism.
It is possible to inhibit HK-II activity with 3-bromopyruvate, and thus re-establish iiver-type 
fructose metabolism in hepatoma cells, including HepG2 (Speicher, et al. 2010). However, 
3-bromopyruvate has also been shown to alter mitochondrial metabolism in HepG2 cells, 
leading to HepG2 cell death with relatively little inhibition of HK-II (Pereira da Silva, et al. 
2009). This makes 3-bromopyruvate an attractive future avenue for cancer treatm ent, but 
may not mean it is necessarily useful for modifying HepG2-based cell culture models for 
investigating fructose metabolism.
4.4 Effect of the Routine Concentration of Culture Media Glucose on 
HepG2 Fuel Utilisation
Cell culture media glucose concentrations may also indirectly exert an inverse influence on
the disposal of fatty acids from lipid treatments of HepG2 cells through modifying the
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extent to which the HepG2 cells are generating energy via mitochondrial (3-oxidation. It has 
been found that hepatoma cells can modify how they meet their energy requirements 
according to the availability of glucose, and that mitochondrial oxidative phosphorylation is 
not completely inactive, but is instead merely repressed if the cell can meet its ATP needs 
through glycolysis provided sufficient glucose is available (Domenis, et al. 2012). A study of 
the culture of HepG2 cells in glucose-free media (Weber, et al. 2002) to make the cells 
exclusively dependent upon mitochondrial oxidative phosphorylation indicated that in 
response, HepG2 cells increased mitochondrial biogenesis, mtDNA, mtRNA and protein 
content, and a two-fold increase in cytochrome c activity was measured, all indicative of an 
increased reliance upon oxidative phosphorylation under aglycaemic culture conditions. 
These changes were accompanied by a decrease in lactate production and an increased 
consumption of glutamine as an alternative fuel substrate, without change to the ATP/ADP 
ratio within the cells. More recent work by Domenis and co-workers (Domenis, et al. 2012), 
demonstrated that in HepG2 cells, hyperglycaemic culture conditions altered mitochondrial 
morphology, with particular changes to the organisation and expression of ATP synthase.
There is also the recently investigated issue of how high glucose culture conditions not only 
repress mitochondrial oxidative phosphorylation, but also diminish mitochondrial 
biogenesis, mitochondrial-DNA copy number, decrease O2 utilisation by HepG2 celis and 
diminish the proton-gradient across the mitochondrial membrane, in addition to altering 
the mitochondrial super-structural organisation (Palmeira, et al. 2007). These findings 
(Weber, et al. 2002, Domenis, et al. 2012, Palmeira, et al. 2007), are relevant to the design 
of iipid-treatment models utilising hepatoma cells, as routine culture in low-glucose 
conditions would therefore enable the cells to dispose of a higher proportion of the lipid 
that they are treated with by oxidative phosphorylation, thus hindering efforts to induce 
lipid accumulation.
4.5 Expression of CyclinDl in HepG2 May Inhibit De Novo 
Lipogenesis through Inhibition of HNF4a
Transformed cells have an altered expression of cyclins that control cell-cycle progression
via cyclin-dependent kinases (Malumbres 2007). CyclinDl directs the cell cycle towards 
proliferation and inhibits differentiated functions (Sladek 2012). A recent paper (Hanse, et 
al. 2012) has identified that one of the targets of cyclinDl is HNF4a, which controls 
differentiated functions including hepatic de novo lipogenesis. This group showed that
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overexpression of cyclinDl lead to inhibition of de novo lipogenesis in mouse primary 
hepatocytes because cyclinDl inhibited the activity of HNF4a, without which the action of 
the glucose-sensing transcription factor ChREBP was in turn inhibited, causing down- 
regulation of the enzymes for de novo lipogenesis. Conversely, siRNA inhibition of cyclinDl 
in the mouse hepatoma cell-line AML-12 resulted in re-instatement HNF4a activity and of 
lipogenesis via ChREBP action. Hanse and co-workers did not directly measure the 
incorporation of glucose or fructose into new lipid per se. Instead, incorporation of "^*C 
acetyl units was quantified in the mouse primary hepatocytes and AML-12 cells. Thus, it is 
not necessarily appropriate yet to conclude that action of cyclinDl and inhibition of HNF4a 
and ChREBP are preventing de novo lipogenesis from those carbon sources in the HepG2 
cells used for the present studies. However, the reported roles of cyclinDl and HNF4a with 
respect to control of lipogenesis in primary mouse and mouse AML-12 hepatoma cells may 
warrant further investigation of their roles with regards to control of lipogenesis in HepG2.
4.6 Hormonal Requirements for Primary Hepatocytes
In the studies presented here, mouse primary hepatocytes were isolated and cultured as an
alternative to HepG2 hepatoma cells once it was found that HepG2 cells did not 
accumulate intracellular TAG following fructose and fructose-glucose treatments. The 
primary hepatocytes were found to have very high levels of intracellular lipid soon after 
having been isolated, despite the livers not appearing steatotic prior to isolation, and 
expert assessment of un-treated liver sections concluding that they were not steatotic 
either. Subsequent to those experiments, further literature review suggested that inclusion 
of the synthetic glucocorticoid dexamethasone in the primary culture media should re­
establish efficient intracellular transport of lipid and its export from the primary 
hepatocytes as VLDL-TAG. Future studies utilising mouse primary hepatocytes should be 
directed at establishing the effect of dexamethasone, and of insulin upon the intracellular 
lipid content of the isolated hepatocytes, before then returning to studies of the effect 
fructose treatments.
4.7 Summary and Future Directions
It is well established that obesity-related conditions and diseases such as insulin resistance, 
type 2 diabetes and cardiovascular disease are associated with excess energy intake and 
dysregulation of hepatic glucose and lipid metabolism. NAFLD is strongly associated with 
the metabolic syndrome, type 2 diabetes and cardiovascular disease. Hepatic TAG
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accumulation is a defining feature of NAFLD, and can occur through both oversupply of 
plasma NEFA to the liver, and from increased hepatic DNL resulting from oversupply of 
carbohydrate to the liver.
This project sought to establish and optimise a robust model system for testing the effects 
of fructose on HepG2 human hepatocytes, with particular interest in how fructose 
treatments to this in vitro model could affect the intracellular TAG content of HepG2, as 
well as hepatocyte viability. It was an unexpected finding that fructose treatments altered 
neither HepG2 intracellular lipid content, nor cell viability. As a result, additional 
experiments were performed to verify whether the intracellular lipid content of the  
available HepG2 cells could be altered by means of fatty acid treatments with PA and OA, in 
accordance with a HuH7 human hepatocyte model previously established in this lab, and in 
accordance with other Iipid-treatment models detailed in the literature (reviewed in 
Chavez-Tapia et al, 2011). It was subsequently found that HepG2 cells had a relatively 
muted response to PA treatments in terms of lipid accumulation.
In parallel with this scheme of research, other investigations looked to establish a robust 
mouse primary hepatocyte model for testing the effects of fructose and lipid treatments on 
primary hepatocyte intracellular lipid content and cell viability. These studies were 
hampered by the discovery that isolated mouse primary hepatocytes routinely had very 
high levels of intracellular lipid soon after isolation, and that this presence of intracellular 
lipid did not permit experiments to test the effect of fructose, glucose or lipid treatments  
on primary hepatocyte lipid content.
As HepG2 cells have been shown to constitutively express apoBlOO VLDL, then sampling of 
cell culture treatm ent media before treatm ent and over time during a carbohydrate or 
fatty acid treatm ent experiment could help to account for the uptake of carbohydrate or 
fatty acids, as well as provide information on whether substrate is being metabolised or 
else exported from the cells. Multiple stable isotope techniques might also be useful to 
confirm if fructose were actually being metabolised by treated cells. Comparison of HepG2 
cells obtained from different sources or laboratories to similar treatments could also shed 
light on any differences in response to those treatments, perhaps providing information on 
phenotypic drift between different sources of HepG2 cells and over time within the same 
laboratory.
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In order to establish a robust primary hepatocyte model system for similar investigations, 
care should be exercised to ensure that the experimental animals are of similar age and 
gender, in order to rule out variation before committing to experiments. Attention must 
also be paid to optimising the correct culture conditions for experiments, bearing in mind 
the work performed in primary hepatocyte culture systems for other applications.
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